

8/13/05 10/693,161

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 18:11:14 ON 13 AUG 2005

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.42

0.42

FILE 'REGISTRY' ENTERED AT 18:12:13 ON 13 AUG 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 AUG 2005 HIGHEST RN 860111-75-7

DICTIONARY FILE UPDATES: 12 AUG 2005 HIGHEST RN 860111-75-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*



Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10693161\10693161f.str



chain nodes :

11 12 13 14 15 16 17 18 19

ring nodes :

1 2 3 4 5 6 7 8 9 10

chain bonds :

1-16 4-11 11-12 12-13 13-14 13-15 16-17 17-18 17-19

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10

exact/norm bonds :

1-2 1-6 1-16 2-3 3-4 4-5 4-11 5-6 5-7 6-10 7-8 8-9 9-10 11-12 12-13  
13-14 13-15 16-17 17-18 17-19

G1:O,S

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:CLASS 12:CLASS 13:CLASS 14:Atom 15:Atom 16:CLASS 17:CLASS 18:CLASS  
19:CLASS

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s L1

SAMPLE SEARCH INITIATED 18:12:35 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 7 TO ITERATE

100.0% PROCESSED 7 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 7 TO 298

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s L1 full

FULL SEARCH INITIATED 18:12:39 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 95 TO ITERATE

100.0% PROCESSED 95 ITERATIONS



0 ANSWERS

SEARCH TIME: 00.00.01

L3 0 SEA SSS FUL L1

=>

Uploading C:\Program Files\Stnexp\Queries\10693161\1069316gf.str



```

chain nodes :
1 2 9 10 11 12 13 14 15 16 17
ring nodes :
3 4 5 6 7 8
chain bonds :
1-14 1-4 2-9 2-3 9-10 10-11 11-12 11-13 14-15 15-16 15-17
ring bonds :
3-4 3-5 4-8 5-6 6-7 7-8
exact/norm bonds :
1-14 1-4 2-9 2-3 3-4 3-5 4-8 5-6 6-7 7-8 11-12 11-13 15-16 15-17
exact bonds :
9-10 10-11 14-15

```

G1:O,S

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 10:CLASS
11:CLASS 12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS

```

L4 STRUCTURE UPLOADED

=> d

L4 HAS NO ANSWERS

L4 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s L4

SAMPLE SEARCH INITIATED 18:14:16 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 24709 TO ITERATE

8.1% PROCESSED 2000 ITERATIONS 0 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 484777 TO 503583  
PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=> s L4 full

FULL SEARCH INITIATED 18:14:20 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 489333 TO ITERATE

100.0% PROCESSED 489333 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.08

L6 0 SEA SSS FUL L4

=> fil reg

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST  | 325.24           | 325.66        |

FILE 'REGISTRY' ENTERED AT 18:16:53 ON 13 AUG 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP.USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 12 AUG 2005 HIGHEST RN 860111-75-7  
DICTIONARY FILE UPDATES: 12 AUG 2005 HIGHEST RN 860111-75-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.


\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS  
for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10693161\10693161g.str



chain nodes :

1 2 9 10 11 12 13 14 15 16 17

ring nodes :

3 4 5 6 7 8

chain bonds :

1-14 2-9 9-10 10-11 11-12 11-13 14-15 15-16 15-17

ring bonds :

3-5 3-4 4-8 5-6 6-7 7-8

exact/norm bonds :

1-14 2-9 3-5 3-4 4-8 5-6 6-7 7-8 11-12 11-13 15-16 15-17

exact bonds :

9-10 10-11 14-15

G1:O,S

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 10:CLASS  
 11:CLASS 12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS 24:CLASS  
 25:CLASS

L7           STRUCTURE UPLOADED

=> d  
L7 HAS NO ANSWERS  
L7           STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s L7  
SAMPLE SEARCH INITIATED 18:17:17 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 19140 TO ITERATE

10.4% PROCESSED           2000 ITERATIONS                           1 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:   ONLINE   \*\*COMPLETE\*\*  
                          BATCH    \*\*COMPLETE\*\*  
PROJECTED ITERATIONS:       374519 TO   391081  
PROJECTED ANSWERS:           6 TO       376

L8           1 SEA SSS SAM L7

=> s L7 full  
FULL SEARCH INITIATED 18:17:24 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 384020 TO ITERATE

100.0% PROCESSED   384020 ITERATIONS                           190 ANSWERS  
SEARCH TIME: 00.00.08

L9           190 SEA SSS FUL L7

=> fil caplus  
COST IN U.S. DOLLARS                           SINCE FILE           TOTAL  
  ENTRY       SESSION  
FULL ESTIMATED COST                           161.33       486.99

FILE 'CAPLUS' ENTERED AT 18:17:44 ON 13 AUG 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Aug 2005   VOL 143 ISS 8  
FILE LAST UPDATED: 12 Aug 2005   (20050812/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s L9

L10            2 L9

=> d ibib abs 1-2



L10 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:370892 CAPLUS  
DOCUMENT NUMBER: 140:374984

TITLE: Preparation of [[diarylethyl]sulfonyl]phenoxy]acetic acids and esters as PPAR activators for treatment of diabetes and related conditions

INVENTOR(S): Jeppesen, Lone; Mogensen, John Patrick; Pettersson, Ingrid; Sauerberg, Per; Pihara, Pavel; Havranek, Miroslav

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.  
SOURCE: PCT Int. Appl., 124 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE     |
|---|------|----------|-----------------|----------|
| WO 2004037776   | A2   | 20040506 | WO 2003-DK722   | 20031027 |
| WO 2004037776   | A3   | 20040610 |                 |          |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW |      |          |                 |          |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  |      |          |                 |          |
| US 2005070583   | A1   | 20050311 | US 2003-693161  | 20031024 |
| CA 2503280  | AA   | 20040506 | CA 2003-2503280 | 20031027 |
| EP 1558572  | A2   | 20050803 | EP 2003-757741  | 20031027 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK   |      |          |                 |          |
| PRIORITY APPLN. INFO.: DK 2002-1631 A 20021028  |      |          |                 |          |
| DK 2003-793 A 20030526  |      |          |                 |          |
| US 2002-423467P P 20021104  |      |          |                 |          |
| WO 2003-DK722 W 20031027  |      |          |                 |          |

OTHER SOURCE(S): MARPAT 140:374984  
OI

L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:220310 CAPLUS  
DOCUMENT NUMBER: 140:270625

TITLE: Preparation of [[bis(biphenyl)allyl]oxy]phenoxy]acetic acids and analogs as PPAR $\delta$  agonists for treatment of diabetes and related conditions

INVENTOR(S): Jeppesen, Lone; Mogensen, John Patrick; Pettersson, Ingrid; Sauerberg, Per; Novo Nordisk A/S, Den.



PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.  
SOURCE: PCT Int. Appl., 78 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE     |
|---|------|----------|-----------------|----------|
| WO 2004022533   | A1   | 20040318 | WO 2003-DK578   | 20030904 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW |      |          |                 |          |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  |      |          |                 |          |
| CA 2499380  | AA   | 20040318 | CA 2003-2499380 | 20030904 |
| US 2004143006   | AA   | 20040722 | US 2003-654699  | 20030904 |
| EP 1537076  | A1   | 20050608 | EP 2003-793608  | 20030904 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK   |      |          |                 |          |
| PRIORITY APPLN. INFO.: DK 2002-1301 A 20020905  |      |          |                 |          |
| DK 2003-784 A 20030523  |      |          |                 |          |
| US 2002-409814P P 20020911  |      |          |                 |          |
| WO 2003-DK578 W 20030904  |      |          |                 |          |

OTHER SOURCE(S): MARPAT 140:270625  
OI

L10 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



AB Title compds. I [wherein X1 and X2 = independently (un)substituted (hetero)aryl; Ar = (un)substituted arylene; Y1 and Y2 = independently O or



S; Z = (CH<sub>2</sub>)<sub>n</sub>; n = 1-3; R1 = H, halo, or optionally halo-substituted (cyclo)alkyl, alkenyl, alkynyl, (hetero)aralkyl, (cyclo)alkoxy, aryloxy, (hetero)aralkoxy, (cyclo)alkylthio, arylthio; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, or aryl; or pharmaceutically acceptable salts, solvates, tautomeric forms, stereoisomers, mixts. of stereoisomers,

or polymorphs thereof] were prepared as peroxisome proliferator activated receptors (PPAR) activators (no data). Thus, I and their pharmaceutical compns. are useful for the treatment and/or prevention of conditions mediated by PPAR, particularly subtype PPAR $\delta$ , such as diabetes, impaired glucose tolerance, insulin resistance, obesity, dyslipidemia, syndrome X, cardiovascular disease, and hypercholesterolemia (no data).

For example, coupling of 4,4'-dibromobenzophenone with tri-Et phosphonacetate in toluene and THF using NaH provided Et 3,3-bis(4-bromophenyl)acrylate (73%). Reduction of the ester to the alc. (76%) using DIBAL-H in THF and toluene, followed by reaction with (4-mercapto-2-methylphenoxy)acetic acid

Me ester in the presence of ADBP and tributylphosphine in THF gave II (88%).

L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



AB Title vinyl carboxylic acid deriva. I [wherein X1 and X3 = independently (un)substituted (hetero)aryl; X2 and X4 = independently (un)substituted (hetero)arylene; Ar = (un)substituted arylene; Y1 and Y2 = independently O or

S; Z = (CH<sub>2</sub>)<sub>n</sub>; n = 1-3; R1 = H, halo, or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, (hetero)aralkyl, (cyclo)alkoxy, aryloxy, (hetero)aralkoxy, (cyclo)alkylthio, arylthio; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, or aryl; or pharmaceutically acceptable salts, solvates,

tautomers, stereoisomers, or polymorphs thereof] were prepared as peroxisome proliferator-activated receptor  $\delta$  (PPAR $\delta$ ) agonists (no data). For example, 4,4'-dibromobenzophenone was coupled with tri-Et phosphonacetate in the presence of NaH in toluene to give Et 3,3-bis(4-bromophenyl)acrylate (73%). Reduction using DIBAL-H in THF (76%),

followed by ADBP-catalyzed condensation with (4-mercapto-2-methylphenoxy)acetic acid Me ester in THF (88%) afforded [4-[3,3-bis(4-bromophenyl)allyl]sulfonyl]-2-methylphenoxy]acetic acid Me ester. Saponification (93%) and substitution with phenylboronic acid using KF,

Pd2(dba)<sub>3</sub>, and Pd[P(t-Bu)<sub>3</sub>]<sub>2</sub> in THF (53%) provided II. Also disclosed is the use of I and their pharmaceutical compns. for the treatment of PPAR $\delta$ -mediated conditions, such as diabetes, impaired glucose tolerance, insulin resistance, or obesity (no data).

REFERENCE COUNT: 7 THESE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

=> d ibib abs 1-2 fhitr


L10 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:370892 CAPLUS  
DOCUMENT NUMBER: 140:374984  
TITLE: Preparation of [[diarylethyl]sulfonyl]phenoxy]acetic acids and esters as PPAR activators for treatment of diabetes and related conditions  
INVENTOR(S): Jeppesen, Lone; Mogensen, John Patrick; Pettersson, Ingrid; Sauerberg, Per; Pihers, Pavel; Havranek, Miroslav  
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.  
SOURCE: PCT Int. Appl., 124 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

| PATENT NO.             | KIND   | DATE     | APPLICATION NO. | DATE       |
|------------------------|--|----------|-----------------|------------|
| WO 2004037776          | A2   | 20040506 | WO 2003-DK722   | 20031027   |
| WO 2004037776          | A3   | 20040610 |                 |            |
| W:                     | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW |          |                 |            |
| RW:                    | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG   |          |                 |            |
| US 2005070583          | A1   | 20050311 | US 2003-693161  | 20031024   |
| CA 2503280             | AA   | 20040506 | CA 2003-2503280 | 20031027   |
| EP 1558572             | A2   | 20050803 | EP 2003-757741  | 20031027   |
| R:                     | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK   |          |                 |            |
| PRIORITY APPLN. INFO.: |  |          | DK 2002-1631    | A 20021028 |
|                        |  |          | DK 2003-793     | A 20030526 |
|                        |  |          | US 2002-423467P | P 20021104 |
|                        |  |          | WO 2003-DK722   | W 20031027 |

OTHER SOURCE(S): MARPAT 140:374984  
GI

L10 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



AB Title compds. I [wherein X1 and X2 = independently (un)substituted (hetero)aryl; Ar = (un)substituted arylene; Y1 and Y2 = independently O or


S; Z = (CH2)n; n = 1-3; R1 = H, halo, or optionally halo-substituted (cyclo)alkyl, alkenyl, alkynyl, (hetero)aryl, (cyclo)alkoxy, aryloxy, (hetero)alkoxy, (cyclo)alkylthio, or arylthio; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, or aryl; or pharmaceutically acceptable salts, solvates, tautomeric forms, stereoisomers, mixts. of stereoisomers,

or polymorphs thereof] were prepared as peroxisome proliferator activated receptors (PPAR) activators (no data). Thus, I and their pharmaceutical compns. are useful for the treatment and/or prevention of conditions mediated by PPAR, particularly subtype PPARδ, such as diabetes, impaired glucose tolerance, insulin resistance, obesity, dyslipidemia, syndrome X, cardiovascular disease, and hypercholesterolemia (no data).

For example, coupling of 4,4'-dibromobenzophenone with tri-*i*-Et phosphonate in toluene and THF using NaH provided Et 3,3-bis(4-bromophenyl)acrylate (73b). Reduction of the ester to the alc. (76a) using DIBAL-H in THF and toluene, followed by reaction with (4-mercapto-2-methylphenoxy)acetic acid Me ester in the presence of ADMP and tributylphosphine in THF gave II (88b).

IT 685138-70-9p, [4-[[3,3-bis(4-bromophenyl)allyloxy]-2-methylphenoxy]acetic acid methyl ester  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(PPAR activator; preparation of  
[[diarylethyl]sulfonyl]phenoxy]acetates as  
PPAR activators for treatment of diabetes and related conditions)  
RN 685138-70-9 CAPLUS  
CN Acetic acid,  
[4-[[3,3-bis(4-bromophenyl)-2-propenyloxy]-2-methylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)

L10 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:220310 CAPLUS  
DOCUMENT NUMBER: 140:270625  
TITLE: Preparation of [[bis(biphenyl)allyloxy]phenoxy]acetic acids and analogs as PPARδ agonists for treatment of diabetes and related conditions  
INVENTOR(S): Jeppesen, Lone; Mogensen, John Patrick; Pettersson, Ingrid; Sauerberg, Per  
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.  
SOURCE: PCT Int. Appl., 78 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

| PATENT NO.             | KIND   | DATE     | APPLICATION NO. | DATE       |
|------------------------|--|----------|-----------------|------------|
| WO 2004022533          | A1   | 20040318 | WO 2003-DK578   | 20030904   |
| W:                     | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW |          |                 |            |
| RW:                    | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG   |          |                 |            |
| CA 2499380             | AA   | 20040318 | CA 2003-2499380 | 20030904   |
| US 2004143006          | A1   | 20040722 | US 2003-654699  | 20030904   |
| EP 1537076             | A1   | 20050608 | EP 2003-793608  | 20030904   |
| R:                     | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK   |          |                 |            |
| PRIORITY APPLN. INFO.: |  |          | DK 2002-1301    | A 20020905 |
|                        |  |          | DK 2003-784     | A 20030523 |
|                        |  |          | US 2002-409814P | P 20020911 |
|                        |  |          | WO 2003-DK578   | W 20030904 |

OTHER SOURCE(S): MARPAT 140:270625  
GI



AB Title vinyl carboxylic acid derivs. I [wherein X1 and X3 = independently (un)substituted (hetero)aryl; X2 and X4 = independently (un)substituted (hetero)arylene; Ar = (un)substituted arylene; Y1 and Y2 = independently


O or S; Z = (CH2)n; n = 1-3; R1 = H, halo, or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, (hetero)aralkyl, (cyclo)alkoxy, aryloxy, (hetero)aralkoxy, (cyclo)alkylthio, arylthio; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, or aryl; or pharmaceutically acceptable salts, solvates, tautomers, stereoisomers, or polymorphs thereof] were prepared as peroxisome

proliferator-activated receptor  $\delta$  (PPAR $\delta$ ) agonists (no data). For example, 4,4'-dibromobenzophenone was coupled with tri-Et phosphonoacetate in the presence of NaH in toluene to give Et 3,3-bis(4-bromophenyl)acrylate (73%). Reduction using DIBAL-H in THF (76%), followed by ADMP-catalyzed condensation with (4-mercapto-2-methylphenoxy)acetic acid Me ester in THF (88%) afforded [4-(3,3-bis(4-bromophenyl)allylsulfanyl)-2-methylphenoxy]acetic acid Me ester. Saponification (93%) and substitution with phenylboronic acid using KF, Pd2(dba)3, and Pd[P(t-Bu)3]2 in THF (53%) provided II. Also disclosed is the use of I and their pharmaceutical compns. for the treatment of PPAR $\delta$ -mediated conditions, such as diabetes, impaired glucose tolerance, insulin resistance, or obesity (no data).

IT 673479-21-59p, [4-([3,3-bis(biphenyl-4-yl)allyloxy]-2-methylphenoxy)acetic acid

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

as (PPAR $\delta$  agonist; preparation of di(hetero)arylvinyl carboxylic acids



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE  
ENTRY  
16.98

TOTAL  
SESSION  
503.97

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE  
ENTRY  
-2.92

TOTAL  
SESSION  
-2.92

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 18:20:17 ON 13 AUG 2005

10/693,16/a. 8/13/05  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 16:56:55 ON 13 AUG 2005

=> fil reg

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST  | 0.21             | 0.21          |

FILE 'REGISTRY' ENTERED AT 16:57:03 ON 13 AUG 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 AUG 2005 HIGHEST RN 860111-75-7  
DICTIONARY FILE UPDATES: 12 AUG 2005 HIGHEST RN 860111-75-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.



\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10693161a.str



```

chain nodes :
1 2 3 4 5 7 8 9 11 12 15 16
chain bonds :
1-3 2-3 3-4 4-5 5-7 7-8 8-9 9-11 11-12 12-15 12-16
exact/norm bonds :
1-3 2-3 3-4 5-7 7-8 8-9 9-11 12-15 12-16
exact bonds :
4-5 11-12

```

G1:O,S

Match level :

```

1:Atom 2:Atom 3:CLASS 4:CLASS 5:CLASS 7:CLASS 8:Atom 9:CLASS 11:CLASS
12:CLASS 15:CLASS 16:CLASS

```

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s L1

SAMPLE SEARCH INITIATED 16:57:19 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 212694 TO ITERATE

0.9% PROCESSED 2000 ITERATIONS 0 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*INCOMPLETE\*\*  
BATCH \*\*INCOMPLETE\*\*

PROJECTED ITERATIONS: EXCEEDS 1000000

PROJECTED ANSWERS: EXCEEDS 0

L2 0 SEA SSS SAM L1

=> s L1 full

FULL SEARCH INITIATED 16:57:23 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - >1,000,000 TO ITERATE

< 12.0% PROCESSED 509617 ITERATIONS 0 ANSWERS

< 17.7% PROCESSED 750811 ITERATIONS 537 ANSWERS

<-----User Break----->

< 21.8% PROCESSED 927924 ITERATIONS 537 ANSWERS

SEARCH ENDED BY USER

SEARCH TIME: 00.00.47

FULL FILE PROJECTIONS: ONLINE \*\*INCOMPLETE\*\*  
BATCH \*\*INCOMPLETE\*\*

PROJECTED ITERATIONS: EXCEEDS 1000000

PROJECTED ANSWERS: EXCEEDS 2313

L3 537 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS

| SINCE FILE | TOTAL   |
|------------|---------|
| ENTRY      | SESSION |
| 161.76     | 161.97  |

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 16:58:15 ON 13 AUG 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Aug 2005 VOL 143 ISS 8



FILE LAST UPDATED: 12 Aug 2005 (20050812/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate  
substance identification.


=> s L3

L4            3 L3

=> d 1-3 ibib abs hitstr

TITLE: Preparation of [(diaryllallyl)sulfanyl]phenoxy]acetic acids and esters as PPAR activators for treatment of diabetes and related conditions  
 INVENTOR(S): Jeppesen, Lone; Mogensen, John Patrick; Pettersson, Ingrid; Sauerberg, Per; Pihera, Pavel; Havranek, Miroslav  
 PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.  
 SOURCE: PCT Int. Appl., 124 pp.  
 CODEN: PIXX02  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.            | KIND   | DATE              | APPLICATION NO. | DATE     |
|-----------------------|--|-------------------|-----------------|----------|
| VO 2004037776         | A2   | 20040506          | VO 2003-DK722   | 20031027 |
| VO 2004037776         | A3   | 20040510          |                 |          |
| W:                    | AL, AG, AI, AM, AN, AR, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HK, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MV, MX, MY, NZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW   |                   |                 |          |
| RW:                   | GH, GM, KE, LS, MV, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, CN, CO, CZ, DE, EG, HU, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MV, MX, MY, NZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW |                   |                 |          |
| US 2005070583         | A1   | 20050331          | US 2003-693161  | 20031024 |
| CA 2503280            | AA   | 20040506          | CA 2003-2503280 | 20031027 |
| EP 1558572            | A2   | 20050803          | EP 2003-757741  | 20031027 |
| R:                    | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK   |                   |                 |          |
| PRIORITY APPL. INFO.: |  |                   |                 |          |
|                       |  | DK 2002-1631      | A               | 20021028 |
|                       |  | DK 2003-793       | A               | 20030526 |
|                       |  | US 2002-423467P   | P               | 20021104 |
|                       |  | WO 2003-DK722     | W               | 20031027 |
| OTHER SOURCE(S):      |  | MARPAT 140:374984 |                 |          |
| G1                    |  |                   |                 |          |




AB Title compds. I [wherein X1 and X2 = independently (un)substituted (hetero)aryl; Ar = (un)substituted arylene; Y1 and Y2 = independently O or S; Z = (CH2)n n = 1-3; R1 = H, halo, or optionally halo-substituted (cyclo)alkyl, alkenyl, alkynyl, (hetero)aryl, (cyclo)alkoxy, aryloxy, (hetero)alkoxy, (cyclo)alkylthio, or arylthio; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, (cyclo)alkoxy, or aryl or pharmaceutically acceptable salts, solvates, tautomeric forms, stereoisomers, mixtures of stereoisomers, or polymorphs thereof] were prepared as peroxisome proliferator activated receptors (PPAR) activators (no data). Thus, I and their pharmaceutical compns. are useful for the treatment and/or prevention of conditions mediated by PPAR, particularly subtype PPAR $\delta$ , such as diabetes, impaired glucose tolerance, insulin resistance, obesity, dyslipidemia, syndrome X, cardiovascular disease, and hypercholesterolemia (no data). For example, coupling of 4,4'-dibromobenzophenone with tri-*t*-butylphosphonate in toluene and THF using NaH provided Et 3,3-bis(4-bromophenyl)acrylate (73). Reduction of the ester to the alc. (76a) using DIBAL-H in THF and toluene, followed by reaction with (4-mercaptoprop-2-ynyl)phenoxy]acetic acid Me ester in the presence of ADOP and tributylphosphine in THF gave II (88%).


IT 673479-08-8P, [4-[[[3,3-bis(4-bromophenyl)allyl]sulfanyl]-2-methylphenoxy]acetic acid methyl ester 685138-63-0P, [4-[[[3,3-bis(4-iodophenyl)allyl]sulfanyl]-2-methylphenoxy]acetic acid methyl ester 685138-66-3P, [4-[[[3,3-bis(4-fluorophenyl)allyl]sulfanyl]-2-methylphenoxy]acetic acid methyl ester 685138-70-9P, [4-[[[3,3-bis(4-bromophenyl)allyloxy]-2-methylphenoxy]acetic acid methyl ester 685138-72-1P, [4-[[[3,3-bis(4-chlorophenyl)allyl]sulfanyl]-2-methylphenoxy]acetic acid methyl ester 685138-77-6P, [4-[[[3,3-bis(3-trifluoromethylphenyl)allyl]sulfanyl]-2-methylphenoxy]acetic acid methyl ester 685138-84-5P, [4-[[[3,3-bis(4-fluorophenyl)allyl]sulfanyl]-2-ethylphenoxy]acetic acid methyl ester 685138-91-6P, [4-[[[3,3-bis(4-chlorophenyl)allyl]sulfanyl]-2-ethylphenoxy]acetic acid methyl ester 685138-95-8P, [4-[[[3,3-bis(3-trifluoromethylphenyl)allyl]sulfanyl]-2-ethylphenoxy]acetic acid methyl ester 685138-97-0P, [4-[[[3,3-bis(4-bromophenyl)allyl]sulfanyl]-2-ethylphenoxy]acetic acid methyl ester 685138-99-2P, [4-[[[3,3-bis(4-bromophenyl)allyl]sulfanyl]-2-chlorophenoxy]acetic acid

methyl ester 685139-12-2P, [4-[[[3,3-bis(4-bromophenyl)-2-ethoxyallyl]sulfanyl]-2-methylphenoxy]acetic acid methyl ester 685139-17-7P, (2)-[4-[[[3-(Benzo[b]thiophen-2-yl)-3-(4-bromophenyl)allyl]sulfanyl]-2-methylphenoxy]acetic acid 685139-21-3P, (2)-[4-[[[3-(4-bromophenyl)-3-(5-methylthiophen-2-yl)allyl]sulfanyl]-2-methylphenoxy]acetic acid 685139-24-6P, [4-[[[3-(Furan-2-yl)-3-(4-trifluoromethylphenyl)allyl]sulfanyl]-2-methylphenoxy]acetic acid 685139-32-6P, (2)-[4-[[[3-(5-Methylthiophen-2-yl)-3-(4-trifluoromethylphenyl)allyl]sulfanyl]-2-methylphenoxy]acetic acid 685139-35-9P, [4-[[[3-(Benzo[b]thiophen-3-yl)-3-(4-trifluoromethylphenyl)allyl]sulfanyl]-2-methylphenoxy]acetic acid 685139-38-2P, [4-[[[3-(Benzo[b]thiophen-2-yl)-3-(4-trifluoromethylphenyl)allyl]sulfanyl]-2-methylphenoxy]acetic acid RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (PPAR activator; prepn. of [(diaryllallyl)sulfanyl]phenoxy]acetates as PPAR activators for treatment of diabetes and related conditions)


RN 673479-08-8 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(4-bromophenyl)-2-propenyl]thio]-2-methylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 685138-63-0 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(4-iodophenyl)-2-propenyl]thio]-2-methylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 685138-66-3 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(4-fluorophenyl)-2-propenyl]thio]-2-methylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 685138-70-9 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(4-bromophenyl)-2-propenyl]oxy]-2-methylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 685138-72-1 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(4-chlorophenyl)-2-propenyl]thio]-2-methylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 685138-77-6 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(3-(trifluoromethyl)phenyl)-2-propenyl]thio]-2-methylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 685138-84-5 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(4-fluorophenyl)-2-propenyl]thio]-2-ethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 685138-91-4 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4-chlorophenyl)-2-propenyl]thio]-2-ethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 685138-95-8 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(3-(trifluoromethyl)phenyl)-2-propenyl]thio]-2-ethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 685138-97-0 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4-bromophenyl)-2-propenyl]thio]-2-ethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 685138-99-2 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4-bromophenyl)-2-propenyl]thio]-2-chlorophenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 685139-24-6 CAPLUS  
CN Acetic acid, [4-[[[3-benzo[b]thien-2-yl-3-(4-(trifluoromethyl)phenyl)-2-propenyl]thio]-2-methylphenoxy]-, (9CI) (CA INDEX NAME)




RN 685139-32-6 CAPLUS  
CN Acetic acid, [2-methyl-4-[[[2,2]-3-(4-(methylthio)phenyl)-3-(4-(trifluoromethyl)phenyl)-2-propenyl]thio]phenoxy]-, (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 685139-35-9 CAPLUS  
CN Acetic acid, [4-[[[3-benzo[b]thien-2-yl-3-(4-(trifluoromethyl)phenyl)-2-propenyl]thio]-2-methylphenoxy]-, (9CI) (CA INDEX NAME)




RN 685139-12-2 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4-bromophenyl)-2-ethoxy-2-propenyl]thio]-2-methylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 685139-17-7 CAPLUS  
CN Acetic acid, [4-[[[2,2]-3-benzo[b]thien-2-yl-3-(4-bromophenyl)-2-propenyl]thio]-2-methylphenoxy]-, (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 685139-21-3 CAPLUS  
CN Acetic acid, [4-[[[2,2]-3-(4-bromophenyl)-3-(4-(methylthio)phenyl)-2-propenyl]thio]-2-methylphenoxy]-, (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 685139-38-2 CAPLUS  
CN Acetic acid, [4-[[[3-benzo[b]thien-2-yl-3-(4-(trifluoromethyl)phenyl)-2-propenyl]thio]-2-methylphenoxy]-, (9CI) (CA INDEX NAME)




IT 673479-09-9P, [4-[[[3,3-Bis(4-bromophenyl)allyl]sulfanyl]-2-methylphenoxy]acetic acid 685138-57-2P, [4-[[[3,3-Bis(4-bromophenyl)allyloxy]-2,6-diphenylphenoxy]acetic acid ethyl ester 685138-61-8P 685138-64-1P, [4-[[[3,3-Bis(4-iodophenyl)allyl]sulfanyl]-2-methylphenoxy]acetic acid 685138-69-6P, [4-[[[3,3-Bis(4-fluorophenyl)allyl]sulfanyl]-2-methylphenoxy]acetic acid 685138-71-0P, [4-[[[3,3-Bis(4-bromophenyl)allyloxy]-2-methylphenoxy]acetic acid 685138-75-4P, [4-[[[3,3-Bis(4-chlorophenyl)allyl]sulfanyl]-2-methylphenoxy]acetic acid 685138-82-3P, [4-[[[3,3-Bis(3-trifluoromethylphenyl)allyl]sulfanyl]-2-methylphenoxy]acetic acid 685138-90-3P, [4-[[[3,3-Bis(4-fluorophenyl)allyl]sulfanyl]-2-ethylphenoxy]acetic acid 685138-93-6P, [4-[[[3,3-Bis(4-chlorophenyl)allyl]sulfanyl]-2-ethylphenoxy]acetic acid 685138-96-9P, [4-[[[3,3-Bis(3-trifluoromethylphenyl)allyl]sulfanyl]-2-ethylphenoxy]acetic acid 685138-98-1P, [4-[[[3,3-Bis(4-bromophenyl)allyl]sulfanyl]-2-ethylphenoxy]acetic acid 685139-10-0P, [4-[[[3,3-Bis(4-bromophenyl)allyl]sulfanyl]-2-chlorophenoxy]acetic acid 685139-15-3P, [4-[[[3,3-Bis(4-bromophenyl)-2-ethoxyallyl]sulfanyl]-2-methylphenoxy]acetic acid 685139-20-2P 685139-23-5P 685139-31-5P 685139-34-8P 685139-37-1P 685139-40-6P 685139-41-7P, [4-[[[3,3-Bis(4-chlorophenyl)allyloxy]phenoxy]acetic acid 685139-43-9P, [4-[[[3,3-Bis(4-chlorophenyl)allyl]sulfanyl]-2-chlorophenoxy]acetic acid 685139-46-2P, [4-[[[3,3-Bis(4-chlorophenyl)allyl]sulfanyl]-2-trifluoromethylphenoxy]acetic acid 685139-48-4P,

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 [4-[[[3,3-bis(3-methylthiophen-2-yl)allyl]sulfonyl]-2-trifluoromethylphenoxy]acetic acid 685139-51-9P,  
 [4-[[[3,3-bis(2-yl)allyl]sulfonyl]-2-trifluoromethylphenoxy]acetic acid 685139-53-1P, [4-[[[3,3-bis(4-iodophenyl)allyl]sulfonyl]-2-methoxyphenoxy]acetic acid 685139-56-4P, [4-[[[3,3-bis(4-chlorophenyl)allyl]sulfonyl]-2-methoxyphenoxy]acetic acid  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (PPAR activator; prepn. of [[diarylallyl]sulfonyl]phenoxy]acetates as PPAR activators for treatment of diabetes and related conditions)  
 RN 673479-09-9 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(4-bromophenyl)-2-propenyl]thio]-2-methylphenoxy]-(9CI) (CA INDEX NAME)



RN 685138-57-2 CAPLUS  
 CN Acetic acid, [[5'-[[[3,3-bis(4-bromophenyl)-2-propenyl]oxy][1,1':3',1''-terphenyl]-2'-yl]oxy]acetate] (9CI) (CA INDEX NAME)




RN 685138-61-8 CAPLUS  
 CN L-Arginine, mono[[5'-[[[3,3-bis(4-bromophenyl)-2-propenyl]oxy][1,1':3',1''-terphenyl]-2'-yl]oxy]acetate] (9CI) (CA INDEX NAME)


CM 1

CRN 685138-60-7  
 CMF C35 H26 Br2 O4


L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 RN 685138-71-0 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(4-bromophenyl)-2-propenyl]thio]-2-methylphenoxy]-(9CI) (CA INDEX NAME)




RN 685138-75-4 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(4-chlorophenyl)-2-propenyl]thio]-2-methylphenoxy]-(9CI) (CA INDEX NAME)



RN 685138-82-3 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(3-(trifluoromethyl)phenyl)-2-propenyl]thio]-2-methylphenoxy]-(9CI) (CA INDEX NAME)




RN 685138-90-3 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(4-fluorophenyl)-2-propenyl]thio]-2-ethylphenoxy]-(9CI) (CA INDEX NAME)



RN 685138-93-6 CAPLUS


L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




CM 2

CRN 74-79-3  
 CMF C6 H14 N4 O2


Absolute stereochemistry.




RN 685138-64-1 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(4-iodophenyl)-2-propenyl]thio]-2-methylphenoxy]-(9CI) (CA INDEX NAME)




RN 685138-69-6 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(4-fluorophenyl)-2-propenyl]thio]-2-methylphenoxy]-(9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, [4-[[[3,3-bis(4-chlorophenyl)-2-propenyl]thio]-2-ethylphenoxy]-(9CI) (CA INDEX NAME)




RN 685138-96-9 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(3-(trifluoromethyl)phenyl)-2-propenyl]thio]-2-ethylphenoxy]-(9CI) (CA INDEX NAME)



RN 685138-98-1 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(4-bromophenyl)-2-propenyl]thio]-2-ethylphenoxy]-(9CI) (CA INDEX NAME)




RN 685139-10-0 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(4-bromophenyl)-2-propenyl]thio]-2-chlorophenoxy]-(9CI) (CA INDEX NAME)



RN 685139-15-5 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(4-bromophenyl)-2-ethoxy-2-propenyl]thio]-2-

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
methylphenoxy]- (9CI) (CA INDEX NAME)




RN 685139-20-2 CAPLUS  
CN L-Lysine, mono[[4-[[[(2Z)-3-benzo[b]thien-2-yl-3-(4-bromophenyl)-2-propenyl]thio]-2-methylphenoxy]acetate] (9CI) (CA INDEX NAME)

CM 1

CRN 685139-17-7  
CMF C26 H21 Br O3 S2


Double bond geometry as shown.



CM 2

CRN 56-87-1  
CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 685139-23-5 CAPLUS  
CN L-Lysine, mono[[4-[[[(2Z)-3-(4-bromophenyl)-3-(4-(methylthio)phenyl)-2-propenyl]thio]-2-methylphenoxy]acetate] (9CI) (CA INDEX NAME)

CM 1

CRN 685139-21-3  
CMF C25 H23 Br O3 S2

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.




RN 685139-34-8 CAPLUS  
CN L-Lysine, mono[[2-methyl-4-[[[(2Z)-3-(4-(methylthio)phenyl)-3-(4-(trifluoromethyl)phenyl)-2-propenyl]thio]phenoxy]acetate] (9CI) (CA INDEX NAME)

CM 1

CRN 685139-32-6  
CMF C26 H23 F3 O3 S2


Double bond geometry as shown.



CM 2

CRN 56-87-1  
CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 685139-37-1 CAPLUS  
CN L-Lysine, mono[[4-[[[3-benzo[b]thien-3-yl-3-(4-(trifluoromethyl)phenyl)-2-propenyl]thio]-2-methylphenoxy]acetate] (9CI) (CA INDEX NAME)

CM 1

CRN 685139-35-9  
CMF C27 H21 F3 O3 S2


L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
Double bond geometry as shown.



CM 2

CRN 56-87-1  
CMF C6 H14 N2 O2


Absolute stereochemistry.



RN 685139-31-5 CAPLUS  
CN L-Lysine, mono[[4-[[[3-(2-furanyl)-3-(4-(trifluoromethyl)phenyl)-2-propenyl]thio]-2-methylphenoxy]acetate] (9CI) (CA INDEX NAME)

CM 1


CRN 685139-24-6  
CMF C23 H19 F3 O4 S



CM 2

CRN 56-87-1  
CMF C6 H14 N2 O2


L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 56-87-1  
CMF C6 H14 N2 O2


Absolute stereochemistry.



RN 685139-40-6 CAPLUS  
CN L-Lysine, mono[[4-[[[3-benzo[b]thien-2-yl-3-(4-(trifluoromethyl)phenyl)-2-propenyl]thio]-2-methylphenoxy]acetate] (9CI) (CA INDEX NAME)

CM 1


CRN 685139-38-2  
CMF C27 H21 F3 O3 S2




CM 2

CRN 56-87-1  
CMF C6 H14 N2 O2


Absolute stereochemistry.




RN 685139-41-7 CAPLUS  
CN Acetic acid, 4-[[[3,3-bis(4-chlorophenyl)-2-propenyl]oxy]phenoxy]- (9CI)  
(CA INDEX NAME)




RN 685139-43-9 CAPLUS  
CN Acetic acid, 4-[[[3,3-bis(4-chlorophenyl)-2-propenyl]thio]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)



RN 685139-46-2 CAPLUS  
CN Acetic acid, 4-[[[3,3-bis(4-chlorophenyl)-2-propenyl]thio]-2-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 685139-48-4 CAPLUS  
CN Acetic acid, 4-[[[3,3-bis(3-methyl-2-thienyl)-2-propenyl]thio]-2-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




IT 685139-19-9P, Ethyl (2)-[4-[[[3-(Benzo[b]thiophen-2-yl)-3-(4-bromophenyl)allyl]sulfonyl]-2-methylphenoxy]acetate 685139-22-4P, Ethyl (2)-[4-[[[3-(4-bromophenyl)-3-(5-methylthiophen-2-yl)allyl]sulfonyl]-2-methylphenoxy]acetate 685139-30-4P, Ethyl (2)-[4-[[[3-(Furan-2-yl)-3-(4-trifluoromethylphenyl)allyl]sulfonyl]-2-methylphenoxy]acetate 685139-33-7P, Ethyl (2)-[4-[[[3-(5-Methylthiophen-2-yl)-3-(4-trifluoromethylphenyl)allyl]sulfonyl]-2-methylphenoxy]acetate 685139-36-9P, Ethyl (2)-[4-[[[3-(Benzo[b]thiophen-3-yl)-3-(4-trifluoromethylphenyl)allyl]sulfonyl]-2-methylphenoxy]acetate 685139-39-3P, Ethyl (2)-[4-[[[3-(Benzo[b]thiophen-2-yl)-3-(4-trifluoromethylphenyl)allyl]sulfonyl]-2-methylphenoxy]acetate 685139-42-6P, [4-[3,3-Bis(4-chlorophenyl)allyloxy]phenoxy]acetic acid ethyl ester 685139-45-1P, [4-[3,3-Bis(4-chlorophenyl)allyl]sulfonyl]-2-chlorophenoxy]acetic acid ethyl ester 685139-47-3P, [4-[3,3-Bis(4-chlorophenyl)allyl]sulfonyl]-2-trifluoromethylphenoxy]acetic acid ethyl ester 685139-50-8P, [4-[[[3,3-Bis(3-methylthiophen-2-yl)allyl]sulfonyl]-2-trifluoromethylphenoxy]acetic acid ethyl ester 685139-52-0P, [4-[[[3,3-Bis(2-furanyl)allyl]sulfonyl]-2-trifluoromethylphenoxy]acetic acid ethyl ester 685139-55-3P, [4-[[[3,3-Bis(4-iodophenyl)allyl]sulfonyl]-2-methoxyphenoxy]acetic acid methyl ester 685139-57-5P, [4-[[[3,3-Bis(4-chlorophenyl)allyl]sulfonyl]-2-methoxyphenoxy]acetic acid methyl ester  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(intermediate preparation of [[diacylallyl]sulfonyl]phenoxy]acetates as PPAR activators for treatment of diabetes and related conditions)

RN 685139-19-9 CAPLUS  
CN Acetic acid, 4-[[[3,3-bis(4-bromophenyl)-3-(4-methylthiophenyl)-2-propenyl]thio]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 685139-22-4 CAPLUS  
CN Acetic acid, 4-[[[3,3-bis(4-bromophenyl)-3-(4-methylthiophenyl)-2-propenyl]thio]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 685139-51-9 CAPLUS  
CN Acetic acid, 4-[[[3,3-bis(4-furanyl)-2-propenyl]thio]-2-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 685139-53-1 CAPLUS  
CN Acetic acid, 4-[[[3,3-bis(4-iodophenyl)-2-propenyl]thio]-2-methoxyphenoxy]- (9CI) (CA INDEX NAME)




RN 685139-56-4 CAPLUS  
CN Acetic acid, 4-[[[3,3-bis(4-chlorophenyl)-2-propenyl]thio]-2-methoxyphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 685139-30-4 CAPLUS  
CN Acetic acid, 4-[[[3,3-bis(4-furanyl)-3-(4-trifluoromethylphenyl)-2-propenyl]thio]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 685139-33-7 CAPLUS  
CN Acetic acid, 2-methyl-4-[[[3,3-bis(4-methylthiophenyl)-3-(4-trifluoromethylphenyl)-2-propenyl]thio]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 685139-36-0 CAPLUS  
CN Acetic acid, 4-[[[3,3-bis(4-bromophenyl)-3-(4-trifluoromethylphenyl)-2-propenyl]thio]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
2-propenyl]thio]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 685139-39-3 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4-chlorophenyl)-2-propenyl]thio]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 685139-42-8 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4-chlorophenyl)-2-propenyl]oxy]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 685139-45-1 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4-chlorophenyl)-2-propenyl]thio]-2-chlorophenoxy]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 685139-55-3 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4-iodophenyl)-2-propenyl]thio]-2-methoxyphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 685139-57-5 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4-chlorophenyl)-2-propenyl]thio]-2-methoxyphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 685139-47-3 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4-chlorophenyl)-2-propenyl]thio]-2-(trifluoromethyl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 685139-50-8 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(3-methyl-2-thienyl)-2-propenyl]thio]-2-(trifluoromethyl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 685139-52-0 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4-chlorophenyl)-2-propenyl]thio]-2-(trifluoromethyl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:370891 CAPLUS  
DOCUMENT NUMBER: 140:391127  
TITLE: Preparation of biphenylallylsulfanylphenoxyacetates and related compounds for treating peroxisome proliferator activated receptor (PPAR) mediated diseases  
INVENTOR(S): Jeppesen, Lone; Pettersson, Ingrid; Sauerberg, Per; Pihl, Pavel; Havranek, Miroslav  
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.  
SOURCE: PCT Int. Appl., 69 pp.  
CODEN: PIXX02  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE       |
|---|------|----------|-----------------|------------|
| WO 2004037775   | A1   | 20040506 | WO 2003-DK723   | 20031027   |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW |      |          |                 |            |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  |      |          |                 |            |
| US 2005080115   | A1   | 20050414 | US 2003-692561  | 20031024   |
| CA 2503276  | AA   | 20040506 | CA 2003-2503276 | 20031027   |
| EP 1558571  | A1   | 20050803 | EP 2003-757742  | 20031027   |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK   |      |          |                 |            |
| PRIORITY APPLN. INFO.:  |      |          | DK 2002-1629    | A 20021028 |
|   |      |          | US 2002-423644P | P 20021104 |
|   |      |          | WO 2003-DK723   | W 20031027 |

OTHER SOURCE(S): MARPAT 140:391127  
GI




AB Title compds. [I: X1, X3 = (substituted) aryl, heteroaryl; X2, Ar = (substituted) aryl, arylene; Y1, Y2 = O, S; Z = (CH2)<sub>n</sub>; n = 1-3; R1 = H, halo, (substituted) alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, heteroalkyl, alkoxy, cycloalkoxy, alkylthio, etc.; R2 = H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, etc.], were prepared for treatment of PPAR mediated disease (no data). Thus, [4-[[3,3-bis(4-bromophenyl)allylsulfanyl]-2-methylphenoxy]acetic acid (preparation given), PhB(OH)2, KP, Pd2(dba)3, and Pd[P(tBu)3]2 were stirred in THF to give [4-[[3-biphenyl-4-yl-3-(4-bromophenyl)allylsulfanyl]phenoxy]acetic acid.  
IT 686774-25-4P 686774-26-5P 686774-27-6P  
686774-28-7P 686774-29-8P 686774-30-1P  
686774-31-2P 686774-32-3P 686774-33-4P

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

686774-34-3P 686774-35-6P 686774-36-7P  
686774-37-8P 686774-38-9P 686774-39-0P  
686774-40-3P 686774-41-4P 686774-42-5P  
686774-43-6P 686774-44-7P 686774-45-8P  
686774-46-9P 686774-47-0P 686774-48-1P  
686774-49-2P 686774-50-3P 686774-51-4P  
686774-52-5P 686774-53-6P 686774-54-7P  
686774-55-8P 686774-56-9P 686774-59-4P  
686774-60-7P 686774-61-8P 686774-62-9P  
686774-63-0P 686774-64-1P 686774-66-3P  
686774-67-4P 686774-68-5P 686774-69-6P  
686774-70-7P 686774-71-8P 686774-72-9P  
686774-73-0P 686774-75-4P 686774-76-5P  
686774-78-7P 686774-79-8P 686774-82-3P  
686774-84-5P 686774-86-7P 686774-88-9P  
686774-90-3P 686774-92-5P 686774-93-6P  
686774-95-8P 686774-96-9P 686774-97-0P  
686774-98-1P 686774-99-2P 686775-01-3P  
686775-03-1P 686775-05-3P 686775-06-4P  
686775-07-5P 686775-08-6P 686775-09-7P  
686775-10-8P 686775-11-9P 686775-12-0P  
686775-13-3P 686775-15-5P 686775-17-7P  
686775-19-9P 686775-21-3P 686775-23-5P  
686775-24-6P 686775-25-7P 686775-27-9P  
686775-29-1P 686775-30-4P 686775-31-5P  
686775-33-7P 686775-34-8P 686775-36-0P  
686775-38-2P 686775-40-6P 686775-43-9P  
686775-44-0P 686775-45-1P 686775-46-2P  
686775-47-3P 686775-48-4P 686775-49-5P  
686775-50-8P 686775-51-9P 686775-52-0P  
686775-53-1P 686775-54-2P 686775-59-7P  
686775-62-2P 686775-64-4P 686775-66-6P  
686775-68-8P


RU: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of biphenylallylsulfanylphenoxyacetates and related compds. for treating peroxisome proliferator activated receptor (PPAR) mediated diseases)

RN 686774-25-4 CAPLUS  
CN Acetic acid, [4-[[3-[1,1'-biphenyl]-4-yl]-3-(4-bromophenyl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 686774-26-5 CAPLUS  
CN Acetic acid, [4-[[3-(4-bromophenyl)-3-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 686774-30-1 CAPLUS  
CN Acetic acid, [4-[[3-(benzo[b]thien-3-yl)-3-[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 686774-31-2 CAPLUS  
CN Acetic acid, [4-[[3-(benzo[b]thien-2-yl)-3-[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 686774-32-3 CAPLUS  
CN Acetic acid, [4-[[3-[1,1'-biphenyl]-4-yl]-3-(5-methyl-2-thienyl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 686774-27-6 CAPLUS  
CN Acetic acid, [4-[[3-(4-bromophenyl)-3-[1,1':4',1''-terphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 686774-28-7 CAPLUS  
CN Acetic acid, [2-methyl-4-[[3-[5-(5-methyl-2-thienyl)-2-benzofuranyl]-3-(2-thienyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 686774-29-8 CAPLUS  
CN Acetic acid, [4-[[3-[1,1'-biphenyl]-4-yl]-3-(2-furanyl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 686774-33-4 CAPLUS  
CN Acetic acid, [4-[[3-(2-fluorophenyl)-3-[1,1'-biphenyl]-4-yl]-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 686774-34-5 CAPLUS  
CN Acetic acid, [4-[[3-(2-fluorophenyl)-3-[1,1'-biphenyl]-4-yl]-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-35-6 CAPLUS




L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-(2-chlorophenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 686774-36-7 CAPLUS  
 CN Acetic acid, [4-[[[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(2-chlorophenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 686774-37-8 CAPLUS  
 CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-(2-bromophenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 686774-40-3 CAPLUS  
 CN Acetic acid, [4-[[[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(2-iodophenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-41-4 CAPLUS  
 CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-(2-methoxyphenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 686774-38-9 CAPLUS  
 CN Acetic acid, [4-[[[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(2-bromophenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-39-0 CAPLUS  
 CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-(2-iodophenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 686774-42-5 CAPLUS  
 CN Acetic acid, [4-[[[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(2-methoxyphenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-43-6 CAPLUS  
 CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-(2-(trifluoromethoxy)phenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-44-7 CAPLUS  
 CN Acetic acid, [4-[[[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(2-(trifluoromethoxy)phenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-45-8 CAPLUS  
 CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-(2-methylphenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-46-9 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-(2-methylphenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-47-0 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-(3-fluorophenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-48-1 CAPLUS




RN 686774-51-6 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-(3-chlorophenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-52-7 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-(3-bromophenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-(2-trifluoromethylphenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 686774-49-2 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-(3-fluorophenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-50-5 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-(3-bromophenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


RN 686774-53-8 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-(3-bromophenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-54-9 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-(3-bromophenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-55-0 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-(3-iodophenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 686774-56-1 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-(3-iodophenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-59-4 CAPLUS  
CN Acetic acid, [4-[[[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(3-methoxyphenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


RN 686774-62-9 CAPLUS  
CN Acetic acid, [4-[[[(2Z)-3-[1,1'-biphenyl]-4-yl-3-[3-(trifluoromethoxy)phenyl]-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-63-0 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-(3-methylphenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-64-1 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-(3-methylphenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-60-7 CAPLUS  
CN Acetic acid, [4-[[[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(3-methoxyphenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-61-8 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-[3-(trifluoromethoxy)phenyl]-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-66-3 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-[3-(trifluoromethyl)phenyl]-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-67-4 CAPLUS  
CN Acetic acid, [4-[[[(2Z)-3-[1,1'-biphenyl]-4-yl-3-[3-(trifluoromethyl)phenyl]-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 RN 686774-68-5 CAPLUS  
 CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-(4-fluorophenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-69-6 CAPLUS  
 CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-(4-fluorophenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-70-9 CAPLUS  
 CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-(4-chlorophenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 686774-75-4 CAPLUS  
 CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-(4-bromophenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-76-5 CAPLUS  
 CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-(4-iodophenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 686774-71-0 CAPLUS  
 CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-(4-chlorophenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 686774-72-1 CAPLUS  
 CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-(4-bromophenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 686774-78-7 CAPLUS  
 CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-(4-iodophenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 686774-79-8 CAPLUS  
 CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-(4-methoxyphenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.






RN 686774-82-3 CAPLUS  
CN Acetic acid, [4-[[[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(4-methoxyphenyl)-2-propenyl]thio]phenoxy]]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-84-5 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-(4-(trifluoromethoxy)phenyl)-2-propenyl]thio]phenoxy]]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-86-7 CAPLUS  
CN Acetic acid, [4-[[[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(4-(trifluoromethoxy)phenyl)-2-propenyl]thio]phenoxy]]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-88-9 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-(4-methylphenyl)-2-propenyl]thio]phenoxy]]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-90-3 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-(4-methylphenyl)-2-propenyl]thio]phenoxy]]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-92-5 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-(4-(trifluoromethyl)phenyl)-2-propenyl]thio]phenoxy]]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-93-6 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-[1,1'-biphenyl]-4-yl-3-(4-(trifluoromethyl)phenyl)-2-propenyl]thio]phenoxy]]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-95-8 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-(4-fluorophenyl)-3-[2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-96-9 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-(4-fluorophenyl)-3-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-97-0 CAPLUS  
CN Acetic acid, [4-[[[(2Z)-3-(4-fluorophenyl)-3-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)




RN 686775-01-9 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-(4-fluorophenyl)-3-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-03-1 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-(4-fluorophenyl)-3-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-98-1 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-(4-fluorophenyl)-3-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-99-2 CAPLUS  
CN Acetic acid, [4-[[[(2Z)-3-(4-fluorophenyl)-3-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-05-3 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-(4-fluorophenyl)-3-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-06-4 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-(4-fluorophenyl)-3-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-07-5 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-(4'-chloro[1,1'-biphenyl]-4-yl)-3-(4-fluorophenyl)-2-propenyl]thio]-2-methylphenoxy]-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-08-6 CAPLUS  
CN Acetic acid, [4-[[[(2Z)-3-(4'-chloro[1,1'-biphenyl]-4-yl)-3-(4-fluorophenyl)-2-propenyl]thio]-2-methylphenoxy]-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-09-7 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-(4-fluorophenyl)-3-(3'-methoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-10-0 CAPLUS  
CN Acetic acid, [4-[[[(2Z)-3-(4-fluorophenyl)-3-(3'-methoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-11-1 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-(4-fluorophenyl)-3-(4'-methoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-12-2 CAPLUS  
CN Acetic acid, [4-[[[(2Z)-3-(4-fluorophenyl)-3-(4'-methoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-13-3 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-(4-chlorophenyl)-3-(2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-15-5 CAPLUS  
CN Acetic acid, [4-[[[(2Z)-3-(4-chlorophenyl)-3-(2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-17-7 CAPLUS  
CN Acetic acid, [4-[[3-(4-chlorophenyl)-3-(3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 686775-19-9 CAPLUS  
CN Acetic acid, [4-[[[2E]-3-(4-chlorophenyl)-3-(3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-21-3 CAPLUS  
CN Acetic acid, [4-[[[2Z]-3-(4-chlorophenyl)-3-(3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-23-5 CAPLUS  
CN Acetic acid, [4-[[[2E]-3-(4-chlorophenyl)-3-(4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-24-6 CAPLUS  
CN Acetic acid, [4-[[[2Z]-3-(4-chlorophenyl)-3-(4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-25-7 CAPLUS  
CN Acetic acid, [4-[[[2E]-3-(3'-chloro[1,1'-biphenyl]-4-yl)-3-(4-chlorophenyl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 686775-27-9 CAPLUS  
CN Acetic acid, [4-[[[2Z]-3-(3'-chloro[1,1'-biphenyl]-4-yl)-3-(4-chlorophenyl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 686775-29-1 CAPLUS  
CN Acetic acid, [4-[[[2E]-3-(4'-chloro[1,1'-biphenyl]-4-yl)-3-(4-chlorophenyl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.






RN 686775-30-4 CAPLUS  
CN Acetic acid, [4-[[[(2Z)-3-(4'-chloro[1,1'-biphenyl]-4-yl)-3-(4-chlorophenyl)-2-propenyl]thio]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-31-5 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-(4-chlorophenyl)-3-(3'-methoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-33-7 CAPLUS  
CN Acetic acid, [4-[[[(2Z)-3-(4-chlorophenyl)-3-(3'-methoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-34-8 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-(4-chlorophenyl)-3-(4'-methoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-36-0 CAPLUS  
CN Acetic acid, [4-[[[(2Z)-3-(4-chlorophenyl)-3-(4'-methoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-38-2 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-(4-bromophenyl)-3-[2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-40-6 CAPLUS  
CN Acetic acid, [4-[[[(2Z)-3-(4-bromophenyl)-3-[2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-43-9 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-(4-bromophenyl)-3-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-44-0 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-(4-bromophenyl)-3-[3'-(trifluoromethyl)1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-45-1 CAPLUS  
CN Acetic acid, [4-[[[(2Z)-3-(4-bromophenyl)-3-[4'-(trifluoromethyl)1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-46-2 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-(4-bromophenyl)-3-[4'-(trifluoromethyl)1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-47-3 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-(4-bromophenyl)-3-[3'-chloro1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-48-4 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-(4-bromophenyl)-3-[3'-chloro1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-49-5 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-(4-bromophenyl)-3-[4'-(trifluoromethyl)1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-50-8 CAPLUS  
CN Acetic acid, [4-[[[(2Z)-3-(4-bromophenyl)-3-[4'-(trifluoromethyl)1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 686775-51-9 CAPLUS  
CN Acetic acid, [4-[[[(2E)-3-(4-bromophenyl)-3-[3'-methoxy1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 686775-52-0 CAPLUS

CN Acetic acid, 4-[[[(2E)-3-(4-bromophenyl)-3-(3'-methoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 686775-53-1 CAPLUS

CN Acetic acid, 4-[[[(2Z)-3-(4-bromophenyl)-3-(4'-methoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 686775-54-2 CAPLUS

CN Acetic acid, 4-[[[(2E)-3-(4-bromophenyl)-3-(4'-methoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-59-7 CAPLUS

CN L-lysine, mono[[2-methyl-4-[[[3-(5-methyl-2-thienyl)-2-benzofuranyl]-3-(2-thienyl)-2-propenyl]thio]phenoxy]acetate] (9CI) (CA INDEX NAME)

CH 1

CRN 686774-28-7

CMF C29 H24 O4 S3




CH 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 686775-62-2 CAPLUS

CN L-lysine, mono[[4-[[[3-(1,1'-biphenyl)-4-yl-3-(2-furanyl)-2-propenyl]thio]-2-methylphenoxy]acetate] (9CI) (CA INDEX NAME)

CH 1

CRN 686774-29-8

CMF C28 H24 O4 S




CH 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 686775-64-4 CAPLUS

CN L-lysine, mono[[4-[[[3-(benzo[b]thien-3-yl-3-[1,1'-biphenyl]-4-yl-2-propenyl]thio]-2-methylphenoxy]acetate] (9CI) (CA INDEX NAME)

CH 1

CRN 686774-30-1

CMF C32 H26 O3 S2




CH 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 686775-66-6 CAPLUS

CN L-lysine, mono[[4-[[[3-(benzo[b]thien-2-yl-3-[1,1'-biphenyl]-4-yl-2-propenyl]thio]-2-methylphenoxy]acetate] (9CI) (CA INDEX NAME)

CH 1

CRN 686774-31-2


CMF C32 H26 O3 S2




CM 2

CRN 56-87-1  
CMF C6 H14 N2 O2

Absolute stereochemistry.

RN 686775-68-8 CAPLUS  
CN L-lysine, mono[[4-[[3-[[1,1'-biphenyl]-4-yl-3-(5-methyl-2-thienyl)-2-propenyl]thio]-2-methylphenoxy]acetate] (9CI) (CA INDEX NAME)



CM 1

CRN 686774-32-3  
CMF C29 H26 O3 S2







CM 2

CRN 56-87-1  
CMF C6 H14 N2 O2


Absolute stereochemistry.

RN 686775-58-6 CAPLUS  
CN Acetic acid, [2-methyl-4-[[3-[[5-(5-methyl-2-thienyl)-2-benzofuranyl]-3-(2-thienyl)-2-propenyl]thio]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)RN 686775-61-1 CAPLUS  
CN Acetic acid, [4-[[[2,2]-3-[[1,1'-biphenyl]-4-yl-3-(2-furanyl)-2-propenyl]thio]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.


IT 673479-08-8P 673479-09-9P 686775-57-5P  
686775-58-6P 686775-61-1P 686775-63-3P  
686775-65-5P 686775-67-7P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
for (preparation of biphenylallylsulfanylphenoxyacetates and related compds. treating peroxisome proliferator activated receptor (PPAR) mediated diseases)  
RN 673479-08-8 CAPLUS  
CN Acetic acid, [4-[[3,3-bis(4-bromophenyl)-2-propenyl]thio]-2-methylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)RN 673479-09-9 CAPLUS  
CN Acetic acid, [4-[[3,3-bis(4-bromophenyl)-2-propenyl]thio]-2-methylphenoxy]-, (9CI) (CA INDEX NAME)RN 686775-57-5 CAPLUS  
CN Acetic acid, [4-[[3-[[5-bromo-2-benzofuranyl]-3-(2-thienyl)-2-propenyl]thio]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)RN 686775-63-3 CAPLUS  
CN Acetic acid, [4-[[3-benzo[b]thien-3-yl-3-[[1,1'-biphenyl]-4-yl-2-propenyl]thio]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)RN 686775-65-5 CAPLUS  
CN Acetic acid, [4-[[3-benzo[b]thien-2-yl-3-[[1,1'-biphenyl]-4-yl-2-propenyl]thio]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)RN 686775-67-7 CAPLUS  
CN Acetic acid, [4-[[[2,2]-3-[[1,1'-biphenyl]-4-yl-3-(5-methyl-2-thienyl)-2-propenyl]thio]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



ACCESSION NUMBER: 2004:220310 CAPLUS  
 DOCUMENT NUMBER: 140:270625  
 TITLE: Preparation of [[bis(biphenyl)allyl]oxy]phenoxy]acetic acids and analogs as PPAR $\delta$  agonists for treatment of diabetes and related conditions  
 INVENTOR(S): Jeppesen, Lone; Mogensen, John Patrick; Patterson, Ingrid; Sauerberg, Per  
 PATENT ASSIGNEE(S): Novo Nordisk A/s, Den.  
 SOURCE: PCT Int. Appl., 78 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.            | KIND   | DATE              | APPLICATION NO. | DATE       |
|-----------------------|--|-------------------|-----------------|------------|
| WO 2004022533         | A1   | 20040318          | WO 2003-DK578   | 20030904   |
| W:                    | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HP, HU, ID, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW |                   |                 |            |
| RW:                   | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, SN, TD, TG   |                   |                 |            |
| CA 2499380            | AA   | 20030918          | CA 2003-249380  | 20030904   |
| US 2004143006         | A1   | 20040722          | US 2003-654699  | 20030904   |
| EP 1537076            | A1   | 20050608          | EP 2003-793608  | 20030904   |
| R:                    | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK   |                   |                 |            |
| PRIORITY APPL. INFO.: |  |                   | DK 2002-1301    | A 20020905 |
|                       |  |                   | DK 2003-784     | A 20030523 |
|                       |  |                   | US 2002-409814P | F 20020911 |
|                       |  |                   | WO 2003-DK578   | P 20030904 |
| OTHER SOURCE(S):      |  | MARPAT 140:270625 |                 |            |
| GI                    |  |                   |                 |            |



AB Title vinyl carboxylic acid derivs. I [wherein X1 and X3 = independently (un)substituted (hetero)aryl; X2 and X4 = independently (un)substituted (hetero)arylene; Ar = (un)substituted arylene; Y1 and Y2 = independently O or S; Z = (CH<sub>2</sub>)<sub>n</sub>; n = 1-3; R1 = H, halo, or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, (hetero)aralkyl, (cyclo)alkoxy, aryloxy, (hetero)alkoxy, (cyclo)alkylthio, arylthio; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, or aryl; or pharmaceutically acceptable salts, solvates, tautomers, stereoisomers, or polymorphs thereof] were prepared as peroxisome proliferator-activated receptor  $\delta$  (PPAR $\delta$ ) agonists (no data). For example, 4,4'-dibromobenzophenone was coupled with tri-Et phosphonoacetate in the presence of NaH in toluene to give Et 3,3-bis(4-bromophenyl)acrylate (73%). Reduction using DIBAL-H in THF (76%), followed by ADMP-catalyzed condensation with (4-mercapto-2-methylphenoxy)acetic acid Me ester in THF (88%) afforded [4-[[3,3-bis(4-bromophenyl)allyl]sulfonyl]-2-methylphenoxy]acetic acid Me ester. Saponification (93%) and substitution with phenylboronic acid using


KF, Pd2(dba)<sub>3</sub> and Pd[P(t-Bu)<sub>3</sub>]<sub>2</sub> in THF (53%) provided II. Also disclosed is the use of I and their pharmaceutical compns. for the treatment of PPAR $\delta$ -mediated conditions, such as diabetes, impaired glucose tolerance, insulin resistance, or obesity (no data).  
 IT 673479-07-7P, [4-[[3,3-Bis(biphenyl-4-yl)allyl]sulfonyl]-2-methylphenoxy]acetic acid 673479-10-2P, [4-[[3,3-Bis(4'-methanesulfonylbiphenyl-4-yl)allyl]sulfonyl]-2-methylphenoxy]acetic acid 673479-11-3P, [4-[[3,3-Bis(3'-trifluoromethylbiphenyl-4-yl)allyl]sulfonyl]-2-methylphenoxy]acetic acid 673479-12-4P, 673479-13-5P, [4-[[3,3-Bis(3'-dimethylcarbamoylbiphenyl-4-yl)allyl]sulfonyl]-2-methylphenoxy]acetic acid 673479-14-6P, [4-[[3,3-Bis(4-(pyridin-3-yl)phenyl)allyl]sulfonyl]-2-methylphenoxy]acetic acid 673479-15-7P, [4-[[3,3-Bis(4-(pyridin-3-yl)phenyl)allyl]sulfonyl]-2-trifluoromethylphenoxy]acetic acid 673479-21-5P, [4-[[3,3-Bis(biphenyl-4-yl)allyl]oxy]-2-methylphenoxy]acetic acid 673479-22-6P, [4-[[3,3-Bis(4-(5-

methylfuran-2-yl)phenyl]allyl]oxy]-2-methylphenoxy]acetic acid 673479-23-7P, [4-[[3,3-Bis(4-(furan-2-yl)phenyl)allyl]oxy]-2-methylphenoxy]acetic acid 673479-24-8P, [4-[[3,3-Bis(4-(5-methylfuran-2-yl)phenyl)allyl]sulfonyl]-2-methylphenoxy]acetic acid 673479-25-9P, [4-[[3,3-Bis(4-(furan-2-yl)phenyl)allyl]sulfonyl]-2-methylphenoxy]acetic acid 673479-26-0P, [4-[[3,3-Bis(4-(5-chlorothiophen-2-yl)phenyl)allyl]sulfonyl]-2-methylphenoxy]acetic acid 673479-27-1P, [4-[[3,3-Bis(4-(5-chlorothiophen-2-yl)phenyl)allyl]oxy]-2-methylphenoxy]acetic acid 673479-28-2P, [4-[[3,3-Bis(4-(thiophen-2-yl)phenyl)allyl]oxy]-2-methylphenoxy]acetic acid 673479-29-3P, [4-[[3,3-Bis(4-(thiophen-2-yl)phenyl)allyl]sulfonyl]-2-methylphenoxy]acetic acid 673479-30-6P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]sulfonyl]-2-methylphenoxy]acetic acid 673479-31-7P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]-2-methylphenoxy]acetic acid 673479-32-8P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673479-33-9P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)-2-ethylallyl]sulfonyl]-2-methylphenoxy]acetic acid 673479-34-0P, [4-[[3,3-Bis(4-(dimethylcarbamoyl)biphenyl-4-yl)allyl]oxy]-2-methylphenoxy]acetic acid 673479-35-1P, [4-[[3,3-Bis(3'-methylsulfonylbiphenyl-4-yl)allyl]sulfonyl]-2-methylphenoxy]acetic acid 673479-36-2P, [4-[[3,3-Bis(3'-methylsulfonylbiphenyl-4-yl)allyl]oxy]-2-methylphenoxy]acetic acid 673479-37-3P, [4-[[3,3-Bis(3'-aminobiphenyl-4-yl)allyl]oxy]-2-methylphenoxy]acetic acid 673479-38-4P, [4-[[3,3-Bis(3'-aminobiphenyl-4-yl)allyl]sulfonyl]-2-methylphenoxy]acetic acid 673479-39-5P, [4-[[3,3-Bis(4'-aminobiphenyl-4-yl)allyl]sulfonyl]-2-methylphenoxy]acetic acid 673479-40-6P, [4-[[3,3-Bis(4'-aminobiphenyl-4-yl)allyl]oxy]-2-methylphenoxy]acetic acid 673479-41-7P, [4-[[3,3-Bis(4-(pyridin-2-yl)phenyl)allyl]oxy]-2-methylphenoxy]acetic acid 673479-42-8P, [4-[[3,3-Bis(4-(pyridin-2-yl)phenyl)allyl]sulfonyl]-2-methylphenoxy]acetic acid 673479-43-9P, [4-[[3,3-Bis(4'-(methanesulfonyl)biphenyl-4-yl)allyl]oxy]-2-methylphenoxy]acetic acid 673479-44-0P, [4-[[3,3-Bis(4'-(methoxy)biphenyl-4-yl)allyl]oxy]-2-methylphenoxy]acetic acid 673479-45-3P, [4-[[3,3-Bis(4'-methoxybiphenyl-4-yl)allyl]sulfonyl]-2-methylphenoxy]acetic acid 673479-46-4P, [4-[[3,3-Bis(4'-(trifluoromethoxy)biphenyl-4-yl)allyl]sulfonyl]-2-methylphenoxy]acetic acid 673479-47-5P, [4-[[3,3-Bis(4'-(trifluoromethoxy)biphenyl-4-yl)allyl]oxy]-2-methylphenoxy]acetic acid 673479-48-6P, [4-[[3,3-Bis(4'-methoxybiphenyl-4-yl)allyl]oxy]-2-methylphenoxy]acetic acid 673479-49-7P, [4-[[3,3-Bis(4'-methoxybiphenyl-4-yl)allyl]sulfonyl]-2-methylphenoxy]acetic acid 673479-50-8P, [4-[[3,3-Bis(4'-trifluoromethylbiphenyl-4-yl)allyl]sulfonyl]-2-methylphenoxy]acetic acid 673479-51-9P, [4-[[3,3-Bis(4'-trifluoromethylbiphenyl-4-yl)allyl]oxy]-2-methylphenoxy]acetic acid 673479-52-0P, [4-[[3,3-Bis(4'-chlorobiphenyl-4-yl)allyl]oxy]-2-methylphenoxy]acetic acid 673479-53-3P, [4-[[3,3-Bis(4'-chlorobiphenyl-4-yl)allyl]sulfonyl]-2-methylphenoxy]acetic acid 673479-54-4P, [4-[[3,3-Bis(4'-tert-butylbiphenyl-4-yl)allyl]oxy]-2-methylphenoxy]acetic acid 673479-55-5P, [4-[[3,3-Bis(4'-acetylbiiphenyl-4-yl)allyl]sulfonyl]-2-methylphenoxy]acetic acid 673479-56-6P, [4-[[3,3-Bis(4'-acetylbiiphenyl-4-yl)allyl]oxy]-2-methylphenoxy]acetic acid 673479-57-7P, [4-[[3,3-Bis(4'-phenoxybiphenyl-4-yl)allyl]oxy]-2-methylphenoxy]acetic acid 673479-58-8P, [4-[[3,3-Bis(4'-phenoxybiphenyl-4-yl)allyl]sulfonyl]-2-methylphenoxy]acetic acid 673479-59-9P, [4-[[3,3-Bis(4'-isopropylbiphenyl-4-yl)allyl]sulfonyl]-2-methylphenoxy]acetic acid 673479-60-0P, [4-[[3,3-Bis(4'-isopropylbiphenyl-4-yl)allyl]oxy]-2-methylphenoxy]acetic




L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 673481-76-0P, [4-[[[3,3-Bis(4'-acetylbiaryl-4-yl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673481-79-3P, [4-[[[3,3-Bis(4'-phenoxybiaryl-4-yl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673481-80-6P, [4-[[[3,3-Bis(4'-phenoxybiaryl-4-yl)-2-ethylallyl]sulfonyl]-2-methylphenoxy]acetic acid 673481-82-8P, [4-[[[3,3-Bis(4'-isopropylbiaryl-4-yl)-2-ethylallyl]sulfonyl]-2-methylphenoxy]acetic acid 673481-84-0P, [4-[[[3,3-Bis(4'-isopropylbiaryl-4-yl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673481-87-3P, [4-[[[3,3-Bis(3',4'-difluorobiaryl-4-yl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673481-90-8P, [4-[[[3,3-Bis(3',4'-difluorobiaryl-4-yl)-2-ethylallyl]sulfonyl]-2-methylphenoxy]acetic acid 673481-93-1P, [4-[[[3,3-Bis(3',5'-dichlorobiaryl-4-yl)-2-ethylallyl]sulfonyl]-2-methylphenoxy]acetic acid 673481-94-2P, [4-[[[3,3-Bis(3',5'-dichlorobiaryl-4-yl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673481-97-5P, [4-[[[3,3-Bis(3'-chloro-4'-fluorobiaryl-4-yl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673481-98-6P, [4-[[[3,3-Bis(3'-chloro-4'-fluorobiaryl-4-yl)-2-ethylallyl]sulfonyl]-2-methylphenoxy]acetic acid 673482-00-3P, [4-[[[3,3-Bis(4-(4-methylfuran-2-yl)phenyl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673482-02-5P, [4-[[[3,3-Bis(4-(4-methylfuran-2-yl)phenyl)-2-ethylallyl]sulfonyl]-2-methylphenoxy]acetic acid 673482-05-8P, [4-[[[3,3-Bis(4-(4-chlorothiophen-2-yl)phenyl)-2-ethylallyl]sulfonyl]-2-methylphenoxy]acetic acid 673482-07-0P, [4-[[[3,3-Bis(4-(4-chlorothiophen-2-yl)phenyl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673482-11-6P, [4-[[[3,3-Bis(4-(pyridin-3-yl)phenyl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673482-13-8P, [4-[[[3,3-Bis(4-(pyridin-3-yl)phenyl)-2-ethylallyl]sulfonyl]-2-methylphenoxy]acetic acid 673482-14-9P, [4-[[[3,3-Bis(3'-methoxybiaryl-4-yl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673482-15-1P, [4-[[[3,3-Bis(3'-methoxybiaryl-4-yl)-2-ethylallyl]sulfonyl]-2-methylphenoxy]acetic acid 673482-19-4P, [4-[[[3,3-Bis(3'-(trifluoromethoxy)biaryl-4-yl)-2-ethylallyl]sulfonyl]-2-methylphenoxy]acetic acid 673482-21-8P, [4-[[[3,3-Bis(3'-(trifluoromethoxy)biaryl-4-yl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673482-22-9P, [4-[[[3,3-Bis(3'-methylbiaryl-4-yl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673482-24-1P, [4-[[[3,3-Bis(3'-methylbiaryl-4-yl)-2-ethylallyl]sulfonyl]-2-methylphenoxy]acetic acid 673482-27-4P, [4-[[[3,3-Bis(3'-trifluoromethylbiaryl-4-yl)-2-ethylallyl]sulfonyl]-2-methylphenoxy]acetic acid 673482-29-6P, [4-[[[3,3-Bis(3'-trifluoromethylbiaryl-4-yl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673482-31-0P, [4-[[[3,3-Bis(3'-chlorobiaryl-4-yl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673482-34-3P, [4-[[[3,3-Bis(3'-chlorobiaryl-4-yl)-2-ethylallyl]sulfonyl]-2-methylphenoxy]acetic acid 673482-36-5P, [4-[[[3,3-Bis(3'-tert-butylbiaryl-4-yl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673482-39-8P, [4-[[[3,3-Bis(3'-acetylbiaryl-4-yl)-2-ethylallyl]sulfonyl]-2-methylphenoxy]acetic acid 673482-42-3P, [4-[[[3,3-Bis(3'-acetylbiaryl-4-yl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673482-45-6P, [4-[[[3,3-Bis(3'-phenoxybiaryl-4-yl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673482-48-9P, [4-[[[3,3-Bis(3'-phenoxybiaryl-4-yl)-2-ethylallyl]sulfonyl]-2-methylphenoxy]acetic acid 673482-51-4P, [4-[[[3,3-Bis(3'-isopropylbiaryl-4-yl)-2-ethylallyl]sulfonyl]-2-methylphenoxy]acetic acid  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (PPAR $\delta$  agonist; prepn. of di(hetero)arylvinyl carboxylic acids as

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-13-5 CAPLUS  
 CN Acetic acid, 4-[[[3,3-bis(3'-[(dimethylamino)carbonyl][1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-14-6 CAPLUS  
 CN Acetic acid, 4-[[[3,3-bis(4-(3-pyridinyl)phenyl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 PPAR $\delta$  agonists for treatment of diabetes and related conditions)


RN 673479-07-7 CAPLUS  
 CN Acetic acid, 4-[[[3,3-bis(1,1'-biphenyl)-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 673479-10-2 CAPLUS  
 CN Acetic acid, 4-[[[3,3-bis(4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-11-3 CAPLUS  
 CN Acetic acid, 4-[[[3,3-bis(3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-12-4 CAPLUS  
 CN Acetic acid, 4-[[[3,3-bis(1,1':4',1''-terphenyl)-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 673479-15-7 CAPLUS  
 CN Acetic acid, 4-[[[3,3-bis(4-(3-pyridinyl)phenyl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-21-5 CAPLUS  
 CN Acetic acid, 4-[[[3,3-bis(1,1'-biphenyl)-4-yl)-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-22-6 CAPLUS  
 CN Acetic acid, 4-[[[3,3-bis(4-(5-methyl-2-furanyl)phenyl)-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-23-7 CAPLUS  
CN Acetic acid, 4-[[[3,3-bis[4-(2-furanyl)phenyl]-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-24-8 CAPLUS  
CN Acetic acid, 4-[[[3,3-bis[4-(5-methyl-2-furanyl)phenyl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-25-9 CAPLUS



RN 673479-28-2 CAPLUS  
CN Acetic acid, 4-[[[3,3-bis[4-(2-thienyl)phenyl]-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-29-3 CAPLUS  
CN Acetic acid, 4-[[[3,3-bis[4-(2-thienyl)phenyl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-30-6 CAPLUS

CN Acetic acid, 4-[[[3,3-bis[4-(2-furanyl)phenyl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-26-0 CAPLUS  
CN Acetic acid, 4-[[[3,3-bis[4-(5-chloro-2-thienyl)phenyl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-27-1 CAPLUS  
CN Acetic acid, 4-[[[3,3-bis[4-(5-chloro-2-thienyl)phenyl]-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
CN Acetic acid, 4-[[[3,3-bis[4-(5-acetyl-2-thienyl)phenyl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-31-7 CAPLUS  
CN Acetic acid, 4-[[[3,3-bis[4-(5-acetyl-2-thienyl)phenyl]-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-32-8 CAPLUS  
CN Acetic acid, 4-[[[2-[[bis[4-(5-acetyl-2-thienyl)phenyl]methylene]butoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)








RN 673479-33-9 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis[4-(5-acetyl-2-thienyl)phenyl]methylene]butyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-34-0 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis[3'-[(dimethylamino)carbonyl][1,1'-biphenyl]-4-yl]-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 673479-38-4 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis[3'-(4-aminophenyl)-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-39-5 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis[3'-(4-aminophenyl)-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-40-8 CAPLUS

RN 673479-35-1 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis[3'-(methylthio)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-36-2 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis[3'-(methylthio)[1,1'-biphenyl]-4-yl]-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-37-3 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis[3'-(4-aminophenyl)-4-yl]-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
CN Acetic acid, [4-[[[3,3-bis[3'-(4-aminophenyl)-4-yl]-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-41-9 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis[4-(2-pyridinyl)phenyl]-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-42-0 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis[4-(2-pyridinyl)phenyl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-43-1 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-44-2 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4'-(methoxy[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-45-3 CAPLUS




RN 673479-48-6 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4'-(methyl[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-49-7 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4'-(methyl[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-50-0 CAPLUS




RN 673479-46-4 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4'-(trifluoromethoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-47-5 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4'-(trifluoromethoxy[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-51-1 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4'-(trifluoromethyl[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-52-2 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4'-(chloro[1,1'-biphenyl]-4-yl)-2-propenyl]oxy)-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-53-3 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4'-chloro[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-54-4 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4'-(1,1-dimethylethyl)[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-55-5 CAPLUS




RN 673479-58-8 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4'-phenoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-59-9 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4'-(1-methylethyl)[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-60-2 CAPLUS




RN 673479-56-6 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4'-acetyl[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-57-7 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4'-phenoxy[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-61-3 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(3',4'-difluoro[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-62-4 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(3',4'-difluoro[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-63-5 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(3',5'-difluoro[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-64-6 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(3',5'-dichloro[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-65-7 CAPLUS




RN 673479-68-0 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4-(4-methyl-2-furanyl)phenyl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-69-1 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4-(4-chloro-2-thienyl)phenyl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-66-8 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(3'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-67-9 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4-(4-methyl-2-furanyl)phenyl)-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-70-4 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4-(4-chloro-2-thienyl)phenyl)-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-71-5 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4-(4-acetyl-2-thienyl)phenyl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-72-6 CAPLUS  
CN Acetic acid, [4-[[3,3-bis[4-(4-acetyl-2-thienyl)phenyl]-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-73-7 CAPLUS  
CN Acetic acid, [4-[[2-[bis[4-(4-acetyl-2-thienyl)phenyl]methylene]butoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-74-8 CAPLUS  
CN Acetic acid, [4-[[2-[bis[4-(4-acetyl-2-thienyl)phenyl]methylene]butyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-75-9 CAPLUS  
CN Acetic acid, [4-[[3,3-bis[4-(3-pyridinyl)phenyl]-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-76-0 CAPLUS  
CN Acetic acid, [4-[[3,3-bis[3'-[(dimethylamino)carbonyl][1,1'-biphenyl]-4-yl]-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673479-77-1 CAPLUS  
CN Acetic acid, [4-[[3,3-bis[3'-methoxy[1,1'-biphenyl]-4-yl]-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-78-2 CAPLUS  
CN Acetic acid, [4-[[3,3-bis[3'-methoxy[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 673479-79-3 CAPLUS  
CN Acetic acid, [4-[[3,3-bis[3'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-80-6 CAPLUS  
CN Acetic acid, [4-[[3,3-bis[3'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-81-7 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, [4-[[[3,3-bis(3'-methyl[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)




RN 673479-82-8 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(3'-methyl[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)




RN 673479-83-9 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673479-84-0 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(3'-chloro[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)




RN 673479-85-1 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)




RN 673479-86-2 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, [4-[[[3,3-bis(3'-(1,1-dimethylethyl)[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)




RN 673479-87-3 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(3'-acetyl[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)




RN 673479-88-4 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(3'-acetyl[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673479-89-5 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(3'-phenoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)




RN 673479-90-8 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(3'-phenoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)




RN 673479-91-9 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, [4-[[[3,3-bis(3'-(1-methylethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-92-0 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(2'-(1-methylethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-93-1 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(2',4'-difluoro[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, [4-[[[3,3-bis(2',5'-dichloro[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-97-5 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(2'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-98-6 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(2'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673479-94-2 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(2',4'-difluoro[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-95-3 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(2',5'-difluoro[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-96-4 CAPLUS


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673479-99-7 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(2',4'-difluoro[1,1'-biphenyl]-4-yl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-00-7 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(2',4'-difluoro[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-01-8 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(2',4'-difluoro[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673480-02-9 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis[4-(2-furanyl)phenyl]-2-propenyl]oxy]phenoxy]-(9CI) (CA INDEX NAME)




RN 673480-03-0 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis[4-(5-methyl-2-furanyl)phenyl]-2-propenyl]thio]phenoxy]-(9CI) (CA INDEX NAME)




RN 673480-04-1 CAPLUS


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673480-07-4 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis[4-(2-thienyl)phenyl]-2-propenyl]oxy]phenoxy]-(9CI) (CA INDEX NAME)




RN 673480-08-5 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis[4-(2-thienyl)phenyl]-2-propenyl]thio]phenoxy]-(9CI) (CA INDEX NAME)




RN 673480-09-6 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
CN Acetic acid, [4-[[[3,3-bis[4-(2-furanyl)phenyl]-2-propenyl]thio]phenoxy]-(9CI) (CA INDEX NAME)




RN 673480-05-2 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis[4-(5-chloro-2-thienyl)phenyl]-2-propenyl]thio]phenoxy]-(9CI) (CA INDEX NAME)




RN 673480-06-3 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis[4-(5-chloro-2-thienyl)phenyl]-2-propenyl]oxy]phenoxy]-(9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
CN Acetic acid, [4-[[[3,3-bis[4-(5-acetyl-2-thienyl)phenyl]-2-propenyl]thio]phenoxy]-(9CI) (CA INDEX NAME)




RN 673480-10-9 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis[4-(5-acetyl-2-thienyl)phenyl]-2-propenyl]oxy]phenoxy]-(9CI) (CA INDEX NAME)




RN 673480-11-0 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis[4-(5-acetyl-2-thienyl)phenyl]-2-propenyl]thio]phenoxy]-(9CI) (CA INDEX NAME)







RN 673480-12-1 CAPLWS  
CN Acetic acid, [4-[[2-[bis[4-(5-acetyl-2-thienyl)phenyl]methylene]butyl]thio  
]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-13-2 CAPLUS  
CN Acetic acid, [4-[[3,3-bis[3'-(methylthio)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-14-3 CAPLUS




RN 673480-17-6 CAPLUS  
CN Acetic acid, [4-[[3,3-bis(4'-amino[1,1'-biphenyl]-4-yl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-18-7 CAPLUS  
CN Acetic acid, [4-[[3,3-bis(4'-amino[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-19-8 CAPLUS




RN 673480-15-4 CAPLWS  
CN Acetic acid, [4-[[3,3-bis(3'-amino[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-16-5 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(3'-amino[1,1'-biphenyl]-4-yl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-20-1 CAPLUS  
CN Acetic acid, [4-[[3,3-bis[4-(2-pyridinyl)phenyl]-2-propenyl]thio]phenoxy]-  
(9CI) (CA INDEX NAME)




RN 673480-21-2 CAPLUS  
CN Acetic acid, [4-[[3,3-bis[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-22-3 CAPLUS  
CN Acetic acid, 4-([3,3-bis(4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl)-2-propenyl]oxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-23-4 CAPLUS  
CN Acetic acid, 4-([3,3-bis(4'-(methoxy[1,1'-biphenyl]-4-yl)-2-propenyl]oxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-24-5 CAPLUS




RN 673480-28-9 CAPLUS  
CN Acetic acid, 4-([3,3-bis(4'-(methyl[1,1'-biphenyl]-4-yl)-2-propenyl]oxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-30-3 CAPLUS  
CN Acetic acid, 4-([3,3-bis(4'-(methyl[1,1'-biphenyl]-4-yl)-2-propenyl]thio)phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-32-5 CAPLUS




RN 673480-25-6 CAPLUS  
CN Acetic acid, 4-([3,3-bis(4'-(trifluoromethoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio)phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-26-7 CAPLUS  
CN Acetic acid, 4-([3,3-bis(4'-(trifluoromethoxy[1,1'-biphenyl]-4-yl)-2-propenyl]oxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-33-6 CAPLUS  
CN Acetic acid, 4-([3,3-bis(4'-(trifluoromethyl[1,1'-biphenyl]-4-yl)-2-propenyl]oxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-34-7 CAPLUS  
CN Acetic acid, 4-([3,3-bis(4'-(chloro[1,1'-biphenyl]-4-yl)-2-propenyl]oxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-35-8 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4'-chloro[1,1'-biphenyl]-4-yl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-36-9 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4'-(1,1-dimethylethyl)[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-37-0 CAPLUS



RN 673480-40-5 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4'-phenoxy[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-41-6 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4'-phenoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-42-7 CAPLUS

CN Acetic acid, [4-[[[3,3-bis(4'-acetyl[1,1'-biphenyl]-4-yl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-38-1 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4'-acetyl[1,1'-biphenyl]-4-yl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-39-2 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4'-acetyl[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)


CN Acetic acid, [4-[[[3,3-bis(4'-(1-methylethyl)[1,1'-biphenyl]-4-yl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-43-8 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4'-(1-methylethyl)[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-44-9 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4'-difluoro[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-45-0 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(3',4'-difluoro[1,1'-biphenyl]-4-yl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-46-1 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(3',5'-dichloro[1,1'-biphenyl]-4-yl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)





RN 673480-47-2 CAPLUS




RN 673480-50-7 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4-(4-methyl-2-furanyl)phenyl)-2-propenyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 673480-51-8 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4-(4-methyl-2-furanyl)phenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-48-3 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(3'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-49-4 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(3'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)


RN 673480-52-9 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4-(4-chloro-2-thienyl)phenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-53-0 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4-(4-chloro-2-thienyl)phenyl)-2-propenyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-54-1 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis(4-(4-acetyl-2-thienyl)phenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-55-2 CAPLUS  
CN Acetic acid, [4-[[3,3-bis[4-(4-acetyl-2-thienyl)phenyl]-2-propenyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-56-3 CAPLUS  
CN Acetic acid, [4-[[2-[[bis[4-(4-acetyl-2-thienyl)phenyl]methylene]butoxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-57-4 CAPLUS  
CN Acetic acid, [4-[[2-[[bis[4-(4-acetyl-2-thienyl)phenyl]methylene]butyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-58-5 CAPLUS  
CN Acetic acid, [4-[[3,3-bis[4-(4-acetyl-2-thienyl)phenyl]-2-propenyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-59-6 CAPLUS  
CN Acetic acid, [4-[[3,3-bis[4-(4-acetyl-2-thienyl)phenyl]-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-60-9 CAPLUS  
CN Acetic acid, [4-[[3,3-bis[3'-(methoxy[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-61-0 CAPLUS  
CN Acetic acid, [4-[[3,3-bis[3'-(methoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 673480-62-1 CAPLUS  
CN Acetic acid, [4-[[3,3-bis[3'-(trifluoromethoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-63-2 CAPLUS  
CN Acetic acid, [4-[[3,3-bis[3'-(trifluoromethoxy[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-64-3 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, [4-[[[3,3-bis(3'-methyl[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-65-4 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(3'-methyl[1,1'-biphenyl]-4-yl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-66-5 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673480-67-6 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-68-7 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(3'-chloro[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-69-8 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, [4-[[[3,3-bis(3'-chloro[1,1'-biphenyl]-4-yl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-70-1 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(3'-(1,1-dimethylethyl)[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-71-2 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(3'-acetyl[1,1'-biphenyl]-4-yl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673480-72-3 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(3'-acetyl[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-73-4 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(3'-phenoxy[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-74-5 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, [4-[[[3,3-bis(3'-phenoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-75-6 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(3'-(1-methylethyl)[1,1'-biphenyl]-4-yl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-76-7 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(2'-(1-methylethyl)[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, [4-[[[3,3-bis(2',5'-dichloro[1,1'-biphenyl]-4-yl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-80-3 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(2',5'-dichloro[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-81-4 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(2'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673480-77-8 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(2',4'-difluoro[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-78-9 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(2',4'-difluoro[1,1'-biphenyl]-4-yl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-79-0 CAPLUS


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 673480-83-6 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(2'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-85-8 CAPLUS  
 CN Acetic acid, [4-[[[2-[[bis([1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673480-87-0 CAPLUS  
 CN Acetic acid, [4-[[[2-[[bis([1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 673480-89-2 CAPLUS  
CN Acetic acid, [4-[[2-[[bis[4-(5-methyl-2-furanyl)phenyl]methylene]butoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673480-91-6 CAPLUS  
CN Acetic acid, [4-[[2-[[bis[4-(2-furanyl)phenyl]methylene]butoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673480-94-9 CAPLUS  
CN Acetic acid, [4-[[2-[[bis[4-(5-methyl-2-furanyl)phenyl]methylene]butyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
CN Acetic acid, [4-[[2-[[bis[4-(5-chloro-2-thienyl)phenyl]methylene]butoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-05-5 CAPLUS  
CN Acetic acid, [4-[[2-[[bis[4-(2-thienyl)phenyl]methylene]butoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-08-8 CAPLUS  
CN Acetic acid, [4-[[2-[[bis[4-(2-thienyl)phenyl]methylene]butyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673480-97-2 CAPLUS  
CN Acetic acid, [4-[[2-[[bis[4-(2-furanyl)phenyl]methylene]butyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673480-99-4 CAPLUS  
CN Acetic acid, [4-[[2-[[bis[4-(5-chloro-2-thienyl)phenyl]methylene]butyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-02-2 CAPLUS



RN 673481-11-3 CAPLUS  
CN Acetic acid, [4-[[2-[[bis[3'-[[dimethylamino]carbonyl]-1,1'-biphenyl]-4-yl]methylene]butyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-13-5 CAPLUS  
CN Acetic acid, [4-[[2-[[bis[3'-[[dimethylamino]carbonyl]-1,1'-biphenyl]-4-yl]methylene]butyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)






RN 673481-16-8 CAPLUS

CN Acetic acid, [4-[[2-[bis(3'-(methylthio)[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-19-1 CAPLUS

CN Acetic acid, [4-[[2-[bis(3'-(methylthio)[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-22-6 CAPLUS

CN Acetic acid, [4-[[2-[bis(3'-amino[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-32-8 CAPLUS

CN Acetic acid, [4-[[2-[bis(4'-(2-pyridinyl)phenyl)methylene]butoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-35-1 CAPLUS

CN Acetic acid, [4-[[2-[bis(4'-(2-pyridinyl)phenyl)methylene]butoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-24-8 CAPLUS

CN Acetic acid, [4-[[2-[bis(3'-amino[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-27-1 CAPLUS

CN Acetic acid, [4-[[2-[bis(4'-amino[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-29-3 CAPLUS




RN 673481-36-2 CAPLUS

CN Acetic acid, [4-[[2-[bis(4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-38-4 CAPLUS

CN Acetic acid, [4-[[2-[bis(4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-40-8 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, [4-[[2-[bis(4'-methoxy[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy]-(9CI) (CA INDEX NAME)




RN 673481-42-0 CAPLUS  
 CN Acetic acid, [4-[[2-[bis(4'-methoxy[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy]-(9CI) (CA INDEX NAME)




RN 673481-44-2 CAPLUS  
 CN Acetic acid, [4-[[2-[bis(4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy]-(9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, [4-[[2-[bis(4'-methyl[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy]-(9CI) (CA INDEX NAME)




RN 673481-56-6 CAPLUS  
 CN Acetic acid, [4-[[2-[bis(4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy]-(9CI) (CA INDEX NAME)




RN 673481-58-8 CAPLUS  
 CN Acetic acid, [4-[[2-[bis(4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy]-(9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673481-47-5 CAPLUS  
 CN Acetic acid, [4-[[2-[bis(4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy]-(9CI) (CA INDEX NAME)




RN 673481-50-0 CAPLUS  
 CN Acetic acid, [4-[[2-[bis(4'-methyl[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy]-(9CI) (CA INDEX NAME)




RN 673481-53-3 CAPLUS


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673481-61-3 CAPLUS  
 CN Acetic acid, [4-[[2-[bis(4'-chloro[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy]-(9CI) (CA INDEX NAME)




RN 673481-64-6 CAPLUS  
 CN Acetic acid, [4-[[2-[bis(4'-chloro[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy]-(9CI) (CA INDEX NAME)




RN 673481-67-9 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, [4-[[2-[bis(4'-(1,1-dimethylethyl)[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-70-4 CAPLUS  
 CN Acetic acid, [4-[[2-[bis([1,1':4',1''-terphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-73-7 CAPLUS  
 CN Acetic acid, [4-[[2-[bis(4'-acetyl[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, [4-[[2-[bis(4'-phenoxy[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-82-8 CAPLUS  
 CN Acetic acid, [4-[[2-[bis(4'-(1-methylethyl)[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-84-0 CAPLUS  
 CN Acetic acid, [4-[[2-[bis(4'-(1-methylethyl)[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673481-76-0 CAPLUS  
 CN Acetic acid, [4-[[2-[bis(4'-acetyl[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-79-3 CAPLUS  
 CN Acetic acid, [4-[[2-[bis(4'-phenoxy[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-80-6 CAPLUS


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673481-87-3 CAPLUS  
 CN Acetic acid, [4-[[2-[bis(3',4'-difluoro[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-90-8 CAPLUS  
 CN Acetic acid, [4-[[2-[bis(3',4'-difluoro[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-93-1 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, [4-[[2-[bis(3',5'-dichloro[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-94-2 CAPLUS  
 CN Acetic acid, [4-[[2-[bis(3',5'-dichloro[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-97-5 CAPLUS  
 CN Acetic acid, [4-[[2-[bis(3'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 673481-98-6 CAPLUS  
 CN Acetic acid, [4-[[2-[bis(3'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673482-00-3 CAPLUS  
 CN Acetic acid, [4-[[2-[bis[4-(4-methyl-2-furanyl)phenyl]methylene]butoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 RN 673482-02-5 CAPLUS  
 CN Acetic acid, [4-[[2-[bis[4-(4-methyl-2-furanyl)phenyl]methylene]butyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673482-05-8 CAPLUS  
 CN Acetic acid, [4-[[2-[bis[4-(4-chloro-2-thienyl)phenyl]methylene]butyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673482-07-0 CAPLUS  
 CN Acetic acid, [4-[[2-[bis[4-(4-chloro-2-thienyl)phenyl]methylene]butoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 673482-11-6 CAPLUS  
 CN Acetic acid, [4-[[2-[bis[4-(3-pyridinyl)phenyl]methylene]butoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673482-13-8 CAPLUS  
 CN Acetic acid, [4-[[2-[bis[4-(3-pyridinyl)phenyl]methylene]butyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 RN 673482-14-9 CAPLUS  
 CN Acetic acid, [4-[[2-[bis(3'-methoxy[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)




RN 673482-16-1 CAPLUS  
 CN Acetic acid, [4-[[2-[bis(3'-methoxy[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)



RN 673482-19-4 CAPLUS  
 CN Acetic acid, [4-[[2-[bis(3'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)




RN 673482-27-4 CAPLUS  
 CN Acetic acid, [4-[[2-[bis(3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)




RN 673482-29-6 CAPLUS  
 CN Acetic acid, [4-[[2-[bis(3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methylene]butoxy]]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673482-21-8 CAPLUS  
 CN Acetic acid, [4-[[2-[bis(3'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl)methylene]butoxy]]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)




RN 673482-22-9 CAPLUS  
 CN Acetic acid, [4-[[2-[bis(3'-methyl[1,1'-biphenyl]-4-yl)methylene]butoxy]]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)




RN 673482-24-1 CAPLUS


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673482-31-0 CAPLUS  
 CN Acetic acid, [4-[[2-[bis(3'-chloro[1,1'-biphenyl]-4-yl)methylene]butoxy]]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)




RN 673482-34-3 CAPLUS  
 CN Acetic acid, [4-[[2-[bis(3'-chloro[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy]]- (9CI) (CA INDEX NAME)




RN 673482-36-5 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, [4-[[2-[[bis(3'-(1,1-dimethylethyl)[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673482-39-8 CAPLUS  
 CN Acetic acid, [4-[[2-[[bis(3'-acetyl[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673482-42-3 CAPLUS  
 CN Acetic acid, [4-[[2-[[bis(3'-acetyl[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673482-45-6 CAPLUS  
 CN Acetic acid, [4-[[2-[[bis(3'-phenoxy[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673482-48-9 CAPLUS  
 CN Acetic acid, [4-[[2-[[bis(3'-phenoxy[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 673482-51-4 CAPLUS


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, [4-[[2-[[bis(3'-(1-methylethyl)[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




IT 673482-54-7P, [4-[[[3,3-Bis(3'-isopropylbiphenyl-4-yl)-2-ethoxallyl]oxy]-2-methylphenoxy]acetic acid 673482-56-9P, [4-[[[3,3-Bis(2',4'-difluorobiphenyl-4-yl)-2-ethoxallyl]oxy]-2-methylphenoxy]acetic acid 673482-58-1P, [4-[[[3,3-Bis(2',4'-difluorobiphenyl-4-yl)-2-ethoxallyl]sulfonyl]-2-methylphenoxy]acetic acid 673482-60-5P, [4-[[[3,3-Bis(2',5'-dichlorobiphenyl-4-yl)-2-ethoxallyl]sulfonyl]-2-methylphenoxy]acetic acid 673482-62-7P, [4-[[[3,3-Bis(2',5'-dichlorobiphenyl-4-yl)-2-ethoxallyl]oxy]-2-methylphenoxy]acetic acid 673482-64-9P, [4-[[[3,3-Bis(2'-chloro-4'-fluorobiphenyl-4-yl)-2-ethoxallyl]oxy]-2-methylphenoxy]acetic acid 673482-66-1P, [4-[[[3,3-Bis(2'-chloro-4'-fluorobiphenyl-4-yl)-2-ethoxallyl]sulfonyl]-2-methylphenoxy]acetic acid 673482-71-8P, [4-[[[3,3-Bis(biphenyl-4-yl)-2-ethoxallyl]oxy]-2-methylphenoxy]acetic acid 673482-73-0P, [4-[[[3,3-Bis(4-(5-methylfuran-2-yl)phenyl)-2-ethoxallyl]oxy]-2-methylphenoxy]acetic acid 673482-75-2P, [4-[[[3,3-Bis(4-(furan-2-yl)phenyl)-2-ethoxallyl]oxy]-2-methylphenoxy]acetic acid 673482-77-4P, [4-[[[3,3-Bis(4-(5-methylfuran-2-yl)phenyl)-2-ethoxallyl]sulfonyl]-2-methylphenoxy]acetic acid 673482-79-6P, [4-[[[3,3-Bis(4-(furan-2-yl)phenyl)-2-ethoxallyl]sulfonyl]-2-methylphenoxy]acetic acid 673482-81-0P, [4-[[[3,3-Bis(4-(5-chlorothiophen-2-yl)phenyl)-2-ethoxallyl]sulfonyl]-2-methylphenoxy]acetic acid 673482-83-2P, [4-[[[3,3-Bis(4-(5-chlorothiophen-2-yl)phenyl)-2-ethoxallyl]oxy]-2-methylphenoxy]acetic acid 673482-85-4P, [4-[[[3,3-Bis(4-(thiophen-2-yl)phenyl)-2-ethoxallyl]oxy]-2-methylphenoxy]acetic acid 673482-87-6P, [4-[[[3,3-Bis(4-(thiophen-2-yl)phenyl)-2-ethoxallyl]sulfonyl]-2-methylphenoxy]acetic acid 673482-89-8P, [4-[[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)-2-ethoxallyl]sulfonyl]-2-methylphenoxy]acetic acid 673482-91-2P, [4-[[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)-2-ethoxallyl]oxy]-2-methylphenoxy]acetic acid 673482-92-3P, [4-[[[3,3-Bis(3'-methylsulfonylbiphenyl-4-yl)-2-ethoxallyl]sulfonyl]-2-methylphenoxy]acetic acid 673482-94-5P, [4-[[[3,3-Bis(3'-methylsulfonylbiphenyl-4-yl)-2-ethoxallyl]oxy]-2-methylphenoxy]acetic acid 673482-96-7P, [4-[[[3,3-Bis(3'-aminobiphenyl-4-yl)-2-ethoxallyl]oxy]-2-methylphenoxy]acetic acid 673482-99-0P, [4-[[[3,3-Bis(3'-aminobiphenyl-4-yl)-2-ethoxallyl]sulfonyl]-2-methylphenoxy]acetic acid 673483-02-8P, [4-[[[3,3-Bis(4'-aminobiphenyl-4-yl)-2-ethoxallyl]sulfonyl]-2-methylphenoxy]acetic acid 673483-03-9P, [4-[[[3,3-Bis(4'-aminobiphenyl-4-yl)-2-ethoxallyl]oxy]-2-methylphenoxy]acetic acid 673483-06-2P,

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 [4-[[[3,3-Bis(4-(pyridin-2-yl)phenyl)-2-ethoxallyl]oxy]-2-methylphenoxy]acetic acid 673483-09-5P, [4-[[[3,3-Bis(4-(pyridin-2-yl)phenyl)-2-ethoxallyl]sulfonyl]-2-methylphenoxy]acetic acid 673483-10-8P, [4-[[[3,3-Bis(4'-(methanesulfonyl)biphenyl-4-yl)-2-ethoxallyl]sulfonyl]-2-methylphenoxy]acetic acid 673483-13-1P, [4-[[[3,3-Bis(4'-(methanesulfonyl)biphenyl-4-yl)-2-ethoxallyl]oxy]-2-methylphenoxy]acetic acid 673483-16-4P, [4-[[[3,3-Bis(3'-(dimethylcarbamoyl)biphenyl-4-yl)-2-ethoxallyl]sulfonyl]-2-methylphenoxy]acetic acid 673483-19-7P, [4-[[[3,3-Bis(3'-(dimethylcarbamoyl)biphenyl-4-yl)-2-ethoxallyl]oxy]-2-methylphenoxy]acetic acid 673483-22-2P, [4-[[[3,3-Bis(4'-methoxybiphenyl-4-yl)-2-ethoxallyl]oxy]-2-methylphenoxy]acetic acid 673483-23-3P, [4-[[[3,3-Bis(4'-methoxybiphenyl-4-yl)-2-ethoxallyl]sulfonyl]-2-methylphenoxy]acetic acid 673483-26-6P, [4-[[[3,3-Bis(4'-(trifluoromethoxy)biphenyl-4-yl)-2-ethoxallyl]sulfonyl]-2-methylphenoxy]acetic acid 673483-29-9P, [4-[[[3,3-Bis(4'-(trifluoromethoxy)biphenyl-4-yl)-2-ethoxallyl]oxy]-2-methylphenoxy]acetic acid 673483-32-4P, [4-[[[3,3-Bis(4'-methoxybiphenyl-4-yl)-2-ethoxallyl]oxy]-2-methylphenoxy]acetic acid 673483-35-8P, [4-[[[3,3-Bis(4'-methoxybiphenyl-4-yl)-2-ethoxallyl]sulfonyl]-2-methylphenoxy]acetic acid 673483-39-1P, [4-[[[3,3-Bis(4'-trifluoromethylbiphenyl-4-yl)-2-ethoxallyl]sulfonyl]-2-methylphenoxy]acetic acid 673483-42-6P, [4-[[[3,3-Bis(4'-trifluoromethylbiphenyl-4-yl)-2-ethoxallyl]oxy]-2-methylphenoxy]acetic acid 673483-43-7P, [4-[[[3,3-Bis(4'-chlorobiphenyl-4-yl)-2-ethoxallyl]oxy]-2-methylphenoxy]acetic acid 673483-46-0P, [4-[[[3,3-Bis(4'-chlorobiphenyl-4-yl)-2-ethoxallyl]sulfonyl]-2-methylphenoxy]acetic acid 673483-48-2P, [4-[[[3,3-Bis(4'-tert-butylbiphenyl-4-yl)-2-ethoxallyl]oxy]-2-methylphenoxy]acetic acid 673483-50-6P, [4-[[[3,3-Bis(4'-tert-butylbiphenyl-4-yl)-2-ethoxallyl]sulfonyl]-2-methylphenoxy]acetic acid 673483-52-8P, [4-[[[3,3-Bis(4'-acetylbiiphenyl-4-yl)-2-ethoxallyl]sulfonyl]-2-methylphenoxy]acetic acid 673483-55-1P, [4-[[[3,3-Bis(4'-acetylbiiphenyl-4-yl)-2-ethoxallyl]oxy]-2-methylphenoxy]acetic acid 673483-57-3P, [4-[[[3,3-Bis(4'-phenoxybiphenyl-4-yl)-2-ethoxallyl]oxy]-2-methylphenoxy]acetic acid 673483-59-5P, [4-[[[3,3-Bis(4'-phenoxybiphenyl-4-yl)-2-ethoxallyl]sulfonyl]-2-methylphenoxy]acetic acid 673483-61-9P, [4-[[[3,3-Bis(4'-isopropylbiphenyl-4-yl)-2-ethoxallyl]sulfonyl]-2-methylphenoxy]acetic acid 673483-63-1P, [4-[[[3,3-Bis(4'-isopropylbiphenyl-4-yl)-2-ethoxallyl]oxy]-2-methylphenoxy]acetic acid 673483-65-3P, [4-[[[3,3-Bis(3',4'-difluorobiphenyl-4-yl)-2-ethoxallyl]oxy]-2-methylphenoxy]acetic acid 673483-67-5P, [4-[[[3,3-Bis(3',4'-difluorobiphenyl-4-yl)-2-ethoxallyl]sulfonyl]-2-methylphenoxy]acetic acid 673483-69-7P, [4-[[[3,3-Bis(3',5'-dichlorobiphenyl-4-yl)-2-ethoxallyl]sulfonyl]-2-methylphenoxy]acetic acid 673483-72-2P, [4-[[[3,3-Bis(3',5'-dichlorobiphenyl-4-yl)-2-ethoxallyl]oxy]-2-methylphenoxy]acetic acid 673483-74-4P, [4-[[[3,3-Bis(3'-chloro-4'-fluorobiphenyl-4-yl)-2-ethoxallyl]oxy]-2-methylphenoxy]acetic acid 673483-77-7P, [4-[[[3,3-Bis(3'-chloro-4'-fluorobiphenyl-4-yl)-2-ethoxallyl]sulfonyl]-2-methylphenoxy]acetic acid 673483-79-9P, [4-[[[3,3-Bis(4-(4-methylfuran-2-yl)phenyl)-2-ethoxallyl]oxy]-2-methylphenoxy]acetic acid 673483-81-3P, [4-[[[3,3-Bis(4-(4-methylfuran-2-yl)phenyl)-2-ethoxallyl]sulfonyl]-2-methylphenoxy]acetic acid 673483-84-6P, [4-[[[3,3-Bis(4-(4-chlorothiophen-2-yl)phenyl)-2-ethoxallyl]sulfonyl]-2-methylphenoxy]acetic acid 673483-87-9P, [4-[[[3,3-Bis(4-(4-chlorothiophen-2-yl)phenyl)-2-ethoxallyl]oxy]-2-methylphenoxy]acetic acid 673483-89-1P, [4-[[[3,3-Bis(4-(4-acetylthiophen-2-yl)phenyl)-2-ethoxallyl]sulfonyl]-2-methylphenoxy]acetic acid 673483-91-5P, [4-[[[3,3-Bis(4-(4-acetylthiophen-2-yl)phenyl)-2-ethoxallyl]oxy]-2-methylphenoxy]acetic acid 673483-93-7P, [4-[[[3,3-Bis(4-(pyridin-






RN 673482-66-1 CAPLUS  
CN Acetic acid, [4-[[[2-bis(2'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673482-71-8 CAPLUS  
CN Acetic acid, [4-[[[2-bis(4-(2-ethoxy-3,3-bis(4-(5-methyl-2-furanyl)phenyl)-2-propenyl)oxy]-2-methylphenoxy)]-4-yl]-2-ethoxy-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673482-73-0 CAPLUS  
CN Acetic acid, [4-[[[2-bis(4-(5-methyl-2-furanyl)phenyl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
CN Acetic acid, [4-[[[2-ethoxy-3,3-bis(4-(2-furanyl)phenyl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673482-81-0 CAPLUS  
CN Acetic acid, [4-[[[2-bis(4-(5-chloro-2-thienyl)phenyl)-2-ethoxy-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673482-83-2 CAPLUS  
CN Acetic acid, [4-[[[2-bis(4-(5-chloro-2-thienyl)phenyl)-2-ethoxy-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673482-75-2 CAPLUS  
CN Acetic acid, [4-[[[2-ethoxy-3,3-bis(4-(2-furanyl)phenyl)-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673482-77-4 CAPLUS  
CN Acetic acid, [4-[[[2-ethoxy-3,3-bis(4-(5-methyl-2-furanyl)phenyl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673482-79-6 CAPLUS



RN 673482-85-4 CAPLUS  
CN Acetic acid, [4-[[[2-ethoxy-3,3-bis(4-(2-thienyl)phenyl)-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673482-87-6 CAPLUS  
CN Acetic acid, [4-[[[2-ethoxy-3,3-bis(4-(2-thienyl)phenyl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673482-89-8 CAPLUS



L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, [4-[[[3,3-bis[4-(5-acetyl-2-thienyl)phenyl]-2-ethoxy-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673482-91-2 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis[4-(5-acetyl-2-thienyl)phenyl]-2-ethoxy-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673482-92-3 CAPLUS  
 CN Acetic acid, [4-[[[2-ethoxy-3,3-bis[3'-(methylthio)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673482-94-5 CAPLUS  
 CN Acetic acid, [4-[[[2-ethoxy-3,3-bis[3'-(methylthio)[1,1'-biphenyl]-4-yl]-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673482-96-7 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis[3'-(3-amino[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673482-99-0 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, [4-[[[3,3-bis[3'-(3-amino[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-02-8 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis[4'-(3-amino[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-03-9 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis[4'-(3-amino[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673483-06-2 CAPLUS  
 CN Acetic acid, [4-[[[2-ethoxy-3,3-bis[4-(2-pyridinyl)phenyl]-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-09-5 CAPLUS  
 CN Acetic acid, [4-[[[2-ethoxy-3,3-bis[4-(2-pyridinyl)phenyl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-10-8 CAPLUS


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, [4-[[2-ethoxy-3,3-bis[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 673483-13-1 CAPLUS  
 CN Acetic acid, [4-[[2-ethoxy-3,3-bis[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-16-4 CAPLUS  
 CN Acetic acid, [4-[[3,3-bis[3'-[(dimethylamino)carbonyl][1,1'-biphenyl]-4-yl]-2-ethoxy-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 673483-23-3 CAPLUS  
 CN Acetic acid, [4-[[2-ethoxy-3,3-bis[4'-(methoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-26-6 CAPLUS  
 CN Acetic acid, [4-[[2-ethoxy-3,3-bis[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-29-9 CAPLUS  
 CN Acetic acid, [4-[[2-ethoxy-3,3-bis[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 673483-19-7 CAPLUS  
 CN Acetic acid, [4-[[3,3-bis[3'-[(dimethylamino)carbonyl][1,1'-biphenyl]-4-yl]-2-ethoxy-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-22-2 CAPLUS  
 CN Acetic acid, [4-[[2-ethoxy-3,3-bis[4'-(methoxy[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673483-32-4 CAPLUS  
 CN Acetic acid, [4-[[2-ethoxy-3,3-bis[4'-(methyl[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-36-8 CAPLUS  
 CN Acetic acid, [4-[[2-ethoxy-3,3-bis[4'-(methyl[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-39-1 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, [4-[[[2-ethoxy-3,3-bis(4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-42-6 CAPLUS  
 CN Acetic acid, [4-[[[2-ethoxy-3,3-bis(4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-43-7 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(4'-chloro[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673483-46-0 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(4'-chloro[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-48-2 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(4'-(1,1-dimethylethyl)[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-50-6 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, [4-[[[2-ethoxy-3,3-bis(4'-(1,1'-terphenyl)-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-52-8 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(4'-acetyl[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-55-1 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(4'-acetyl[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673483-57-3 CAPLUS  
 CN Acetic acid, [4-[[[2-ethoxy-3,3-bis(4'-phenoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-59-5 CAPLUS  
 CN Acetic acid, [4-[[[2-ethoxy-3,3-bis(4'-phenoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-61-9 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, [4-[[2-ethoxy-3,3-bis[4'-(1-methylethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-63-1 CAPLUS  
 CN Acetic acid, [4-[[2-ethoxy-3,3-bis[4'-(1-methylethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-65-3 CAPLUS  
 CN Acetic acid, [4-[[3,3-bis(3',4'-difluoro[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673483-67-5 CAPLUS  
 CN Acetic acid, [4-[[3,3-bis(3',4'-difluoro[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-70-0 CAPLUS  
 CN Acetic acid, [4-[[3,3-bis(3',5'-dichloro[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-72-2 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, [4-[[3,3-bis(3',5'-dichloro[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-74-4 CAPLUS  
 CN Acetic acid, [4-[[3,3-bis(3'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-77-7 CAPLUS  
 CN Acetic acid, [4-[[3,3-bis(3'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 673483-79-9 CAPLUS  
 CN Acetic acid, [4-[[2-ethoxy-3,3-bis[4-(4-methyl-2-furanyl)phenyl]-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-81-3 CAPLUS  
 CN Acetic acid, [4-[[2-ethoxy-3,3-bis[4-(4-methyl-2-furanyl)phenyl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 673483-84-6 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis[4-(4-chloro-2-thienyl)phenyl]-2-ethoxy-2-propenyl]thio]-2-methylphenoxy]-(9CI) (CA INDEX NAME)




RN 673483-87-9 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis[4-(4-chloro-2-thienyl)phenyl]-2-ethoxy-2-propenyl]oxy]-2-methylphenoxy]-(9CI) (CA INDEX NAME)




RN 673483-89-1 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis[4-(4-acetyl-2-thienyl)phenyl]-2-ethoxy-2-propenyl]thio]-2-methylphenoxy]-(9CI) (CA INDEX NAME)




RN 673483-95-9 CAPLUS  
 CN Acetic acid, [4-[[[2-ethoxy-3,3-bis[4-(3-pyridinyl)phenyl]-2-propenyl]thio]-2-methylphenoxy]-(9CI) (CA INDEX NAME)




RN 673483-97-1 CAPLUS  
 CN Acetic acid, [4-[[[2-ethoxy-3,3-bis[3'-methoxy[1,1'-biphenyl]-4-yl]-2-propenyl]oxy]-2-methylphenoxy]-(9CI) (CA INDEX NAME)




RN 673483-99-3 CAPLUS  
 CN Acetic acid, [4-[[[2-ethoxy-3,3-bis[3'-methoxy[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]-(9CI) (CA INDEX NAME)




RN 673483-91-5 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis[4-(4-acetyl-2-thienyl)phenyl]-2-ethoxy-2-propenyl]oxy]-2-methylphenoxy]-(9CI) (CA INDEX NAME)




RN 673483-93-7 CAPLUS  
 CN Acetic acid, [4-[[[2-ethoxy-3,3-bis[4-(3-pyridinyl)phenyl]-2-propenyl]oxy]-2-methylphenoxy]-(9CI) (CA INDEX NAME)



RN 673484-01-0 CAPLUS  
 CN Acetic acid, [4-[[[2-ethoxy-3,3-bis[3'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]-(9CI) (CA INDEX NAME)




RN 673484-03-2 CAPLUS  
 CN Acetic acid, [4-[[[2-ethoxy-3,3-bis[3'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]-2-propenyl]oxy]-2-methylphenoxy]-(9CI) (CA INDEX NAME)




RN 673484-05-4 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, {4-[[2-ethoxy-3,3-bis(3'-methyl[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-methylphenoxy}- (9CI) (CA INDEX NAME)




RN 673484-07-6 CAPLUS  
 CN Acetic acid, {4-[[2-ethoxy-3,3-bis(3'-methyl[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy}- (9CI) (CA INDEX NAME)




RN 673484-09-8 CAPLUS  
 CN Acetic acid, {4-[[2-ethoxy-3,3-bis(3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy}- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, {4-[[3,3-bis(3'-chloro[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]thio]-2-methylphenoxy}- (9CI) (CA INDEX NAME)




RN 673484-17-8 CAPLUS  
 CN Acetic acid, {4-[[3,3-bis(3'-(1,1-dimethylethyl)[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]oxy]-2-methylphenoxy}- (9CI) (CA INDEX NAME)




RN 673484-19-0 CAPLUS  
 CN Acetic acid, {4-[[3,3-bis(3'-acetyl[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]thio]-2-methylphenoxy}- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673484-11-2 CAPLUS  
 CN Acetic acid, {4-[[3,3-bis(3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]oxy]-2-methylphenoxy}- (9CI) (CA INDEX NAME)




RN 673484-13-4 CAPLUS  
 CN Acetic acid, {4-[[3,3-bis(3'-chloro[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]oxy]-2-methylphenoxy}- (9CI) (CA INDEX NAME)




RN 673484-15-6 CAPLUS


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673484-21-4 CAPLUS  
 CN Acetic acid, {4-[[3,3-bis(3'-acetyl[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]oxy]-2-methylphenoxy}- (9CI) (CA INDEX NAME)




RN 673484-23-6 CAPLUS  
 CN Acetic acid, {4-[[2-ethoxy-3,3-bis(3'-phenoxy[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-methylphenoxy}- (9CI) (CA INDEX NAME)




RN 673484-25-8 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, [4-[[[2-ethoxy-3,3-bis(3'-phenoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673484-27-0 CAPLUS  
 CN Acetic acid, [4-[[[2-ethoxy-3,3-bis(3'-(1-methylethyl)[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673484-29-2 CAPLUS  
 CN Acetic acid, [4-[[[2-ethoxy-3,3-bis(3'-(1-methylethyl)[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673484-31-6 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(2',4'-difluoro[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673484-33-8 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(2',4'-difluoro[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673484-35-0 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, [4-[[[3,3-bis(2',5'-dichloro[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673484-37-2 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(2',5'-dichloro[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673484-39-4 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(2'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 673484-41-8 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(2'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673484-43-0 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis([1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-45-2 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis([1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)



RN 673484-47-4 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis[4-(5-methyl-2-furanyl)phenyl]-2-propenyl]oxy]-2-chlorophenoxy]]- (9CI) (CA INDEX NAME)




RN 673484-49-6 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis[4-(2-furanyl)phenyl]-2-propenyl]oxy]-2-chlorophenoxy]]- (9CI) (CA INDEX NAME)




RN 673484-51-0 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis[4-(5-methyl-2-furanyl)phenyl]-2-propenyl]thio]-2-chlorophenoxy]]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
CN Acetic acid, [4-[[[3,3-bis[4-(5-chloro-2-thienyl)phenyl]-2-propenyl]oxy]-2-chlorophenoxy]]- (9CI) (CA INDEX NAME)




RN 673484-58-7 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis[4-(2-thienyl)phenyl]-2-propenyl]oxy]-2-chlorophenoxy]]- (9CI) (CA INDEX NAME)




RN 673484-60-1 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis[4-(2-thienyl)phenyl]-2-propenyl]thio]-2-chlorophenoxy]]- (9CI) (CA INDEX NAME)




RN 673484-53-2 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis[4-(2-furanyl)phenyl]-2-propenyl]thio]-2-chlorophenoxy]]- (9CI) (CA INDEX NAME)




RN 673484-54-3 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis[4-(5-chloro-2-thienyl)phenyl]-2-propenyl]thio]-2-chlorophenoxy]]- (9CI) (CA INDEX NAME)




RN 673484-56-5 CAPLUS



RN 673484-62-3 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis[4-(5-acetyl-2-thienyl)phenyl]-2-propenyl]thio]-2-chlorophenoxy]]- (9CI) (CA INDEX NAME)




RN 673484-63-4 CAPLUS  
CN Acetic acid, [4-[[[3,3-bis[4-(5-acetyl-2-thienyl)phenyl]-2-propenyl]oxy]-2-chlorophenoxy]]- (9CI) (CA INDEX NAME)




RN 673484-64-5 CAPLUS



L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, [4-[2-[bis[4-(5-acetyl-2-thienyl)phenyl]methylene]butoxy]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-65-6 CAPLUS  
 CN Acetic acid, [4-[[[3-bis[4-(5-acetyl-2-thienyl)phenyl]methylene]butyl]thio]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-66-7 CAPLUS  
 CN Acetic acid, [4-[[[3-bis[3'-(methylthio)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, [4-[[[3-bis[3'-(methylthio)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-71-4 CAPLUS  
 CN Acetic acid, [4-[[[3-bis[4'-(methylthio)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-72-5 CAPLUS  
 CN Acetic acid, [4-[[[3-bis[4'-(methylthio)[1,1'-biphenyl]-4-yl]-2-propenyl]oxy]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673484-67-8 CAPLUS  
 CN Acetic acid, [4-[[[3-bis[3'-(methylthio)[1,1'-biphenyl]-4-yl]-2-propenyl]oxy]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-68-9 CAPLUS  
 CN Acetic acid, [4-[[[3-bis[3'-(methylthio)[1,1'-biphenyl]-4-yl]-2-propenyl]oxy]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-69-0 CAPLUS


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673484-73-6 CAPLUS  
 CN Acetic acid, [4-[[[3-bis[4-(2-pyridinyl)phenyl]-2-propenyl]oxy]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-74-7 CAPLUS  
 CN Acetic acid, [4-[[[3-bis[4-(2-pyridinyl)phenyl]-2-propenyl]thio]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-75-8 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, [4-[[[3,3-bis[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-76-9 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-propenyl]oxy]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-77-0 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis[4'-(methoxy[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673484-78-1 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis[4'-(methoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-79-2 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis[4'-(trifluoromethoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-80-5 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, [4-[[[3,3-bis[4'-(trifluoromethoxy[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-81-6 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis[4'-(methyl[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-82-7 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis[4'-(trifluoromethyl[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673484-83-8 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis[4'-(trifluoromethyl[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-84-9 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis[4'-(chloro[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-85-0 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, [4-[[[3,3-bis(4'-chloro[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-86-1 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(4'-((1,1-dimethylethyl)[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-87-2 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(4'-((1,1':4',1''-terphenyl)-4-yl)-2-propenyl]thio]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, [4-[[[3,3-bis(4'-phenoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-91-8 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(4'-((1-methylethyl)[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-92-9 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(4'-((1-methylethyl)[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)

RN 673484-96-3 CAPLUS


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673484-88-3 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(4'-acetyl[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-89-4 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(4'-phenoxy[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-90-7 CAPLUS


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673484-93-0 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(3',4'-difluoro[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-94-1 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(3',4'-difluoro[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-96-3 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Acetic acid, [4-[[[3,3-bis(3',5'-dichloro[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-97-4 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(3'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-98-5 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(3'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 673484-99-6 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(3'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




IT 673479-08-8P, [4-[[[3,3-Bis(4-bromophenyl)allyl]sulfanyl]-2-methylphenoxy]acetic acid methyl ester 673479-09-9P, [4-[[[3,3-Bis(4-bromophenyl)allyl]sulfanyl]-2-methylphenoxy]acetic acid 673479-20-4P, [4-[[[3,3-Bis(4-(pyridin-3-yl)phenyl)allyl]sulfanyl]-2-trifluoromethylphenoxy]acetic acid ethyl ester  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; preparation of di(hetero)arylvinyl carboxylic acids as PPAR $\delta$  agonists for treatment of diabetes and related conditions)  
 RN 673479-08-8 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(4-bromophenyl)-2-propenyl]thio]-2-methylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673479-09-9 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(4-bromophenyl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 673479-20-4 CAPLUS  
 CN Acetic acid, [4-[[[3,3-bis(4-(3-pyridinyl)phenyl)-2-propenyl]thio]-2-(trifluoromethyl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs 1-3

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:370892 CAPLUS

DOCUMENT NUMBER: 140:374984

TITLE: Preparation of [[di(aryl)allyl]sulfonyl]phenylacetic acids and esters as PPAR activators for treatment of diabetes and related conditions

INVENTOR(S): Jeppesen, Lone; Mogensen, John Patrick; Pettersson, Ingrid; Sauerberg, Per; Pihera, Pavel; Havranek, Miroslav

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.

SOURCE: PCT Int. Appl., 124 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.             | KIND   | DATE            | APPLICATION NO. | DATE     |
|------------------------|--|-----------------|-----------------|----------|
| WO 2004037776          | A2   | 20040506        | WO 2003-DK722   | 20031027 |
| WO 2004037776          | A3   | 20040610        |                 |          |
| W:                     | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW |                 |                 |          |
| RW:                    | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG   |                 |                 |          |
| US 2005070583          | A1   | 20050331        | US 2003-693161  | 20031024 |
| CA 2503280             | AA   | 20040506        | CA 2003-2503280 | 20031027 |
| EP 1558572             | A2   | 20050803        | EP 2003-757741  | 20031027 |
| R:                     | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK   |                 |                 |          |
| PRIORITY APPLN. INFO.: |  |                 |                 |          |
|                        |  | DK 2002-1631    | A               | 20021028 |
|                        |  | DK 2003-793     | A               | 20030526 |
|                        |  | US 2002-423467P | P               | 20021104 |
|                        |  | WO 2003-DK722   | W               | 20031027 |
| OTHER SOURCE(S):       | MARPAT 140:374984  |                 |                 |          |
| GI                     |  |                 |                 |          |

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:370891 CAPLUS

DOCUMENT NUMBER: 140:391127

TITLE: Preparation of biphenylallylsulfonylphenylacetates and related compounds for treating peroxisome proliferator activated receptor (PPAR) mediated diseases

INVENTOR(S): Jeppesen, Lone; Pettersson, Ingrid; Sauerberg, Per; Pihera, Pavel; Havranek, Miroslav

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.

SOURCE: PCT Int. Appl., 69 pp.


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

| PATENT NO.             | KIND   | DATE            | APPLICATION NO. | DATE     |
|------------------------|--|-----------------|-----------------|----------|
| WO 2004037775          | A1   | 20040506        | WO 2003-DK723   | 20031027 |
| W:                     | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW |                 |                 |          |
| RW:                    | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG   |                 |                 |          |
| US 2005080115          | A1   | 20050414        | US 2003-692561  | 20031024 |
| CA 2503276             | AA   | 20040506        | CA 2003-2503276 | 20031027 |
| EP 1558571             | A1   | 20050803        | EP 2003-757742  | 20031027 |
| R:                     | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK   |                 |                 |          |
| PRIORITY APPLN. INFO.: |  |                 |                 |          |
|                        |  | DK 2002-1629    | A               | 20021028 |
|                        |  | US 2002-423644P | P               | 20021104 |
|                        |  | WO 2003-DK723   | W               | 20031027 |
| OTHER SOURCE(S):       | MARPAT 140:391127  |                 |                 |          |
| GI                     |  |                 |                 |          |



AB Title compds. [I: X1, X3 = (substituted) aryl, heteroaryl; X2, Ar = (substituted) aryl, arylene; Y1, Y2 = O, Si; Z = (CH2)<sub>n</sub>; n = 1-3; R1 = H, halo, (substituted) alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, heteroalkyl, alkoxy, cycloalkoxy, allylthio, etc.; R2 = H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, etc.], were prepared for treatment of PPAR mediated disease (no data). Thus, [4-{3-bis-(4-bromophenyl)allylsulfonyl]-2-methylphenoxy]acetic acid (preparation given), PhB(OH)2, K<sub>2</sub>CO<sub>3</sub>, and Pd(PPh<sub>3</sub>)<sub>4</sub> were stirred in THF to give [4-{3-biphenyl-4-yl-3-(4-bromophenyl)allylsulfonyl]phenoxy]acetic acid.

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



AB Title compds. I (wherein X1 and X2 = independently (un)substituted (hetero)aryl; Ar = (un)substituted arylene; Y1 and Y2 = independently O or Si; Z = (CH2)<sub>n</sub>; n = 1-3; R1 = H, halo, or optionally halo-substituted (cyclo)alkyl, alkenyl, alkynyl, (hetero)aralkyl, (cyclo)alkoxy, aryloxy, (hetero)aralkoxy, (cyclo)alkylthio, or arylthio; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, alkenyl, or aryl; or pharmaceutically acceptable salts, solvates, tautomeric forms, stereoisomers, mixtures of stereoisomers, or polymorphs thereof) were prepared as peroxisome proliferator activated receptors (PPAR) activators (no data). Thus, I and their pharmaceutical compns. are useful for the treatment and/or prevention of conditions mediated by PPAR, particularly subtype PPAR $\delta$ , such as diabetes, impaired glucose tolerance, insulin resistance, obesity, dyslipidemia, syndrome X, cardiovascular disease, and hypercholesterolemia (no data). For example, coupling of 4,4'-dibromobenzophenone with tri-*t*-butyl phosphonate in toluene and THF using NaH provided Et 3,3-bis(4-bromophenyl)acrylate (73%). Reduction of the ester to the alc. (76i) using DIBAL-H in THF and toluene, followed by reaction with (4-mercapto-2-methylphenoxy)acetic acid Me ester in the presence of ADPP and tributylphosphine in THF gave II (88%).

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:220310 CAPLUS

DOCUMENT NUMBER: 140:270625

TITLE: Preparation of [[bis(biphenyl)allyl]oxy]phenyl]acetic acids and analogs as PPAR $\delta$  agonists for treatment of diabetes and related conditions

INVENTOR(S): Jeppesen, Lone; Mogensen, John Patrick; Pettersson, Ingrid; Sauerberg, Per

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.

SOURCE: PCT Int. Appl., 78 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.             | KIND   | DATE            | APPLICATION NO. | DATE     |
|------------------------|--|-----------------|-----------------|----------|
| WO 2004022533          | A1   | 20040318        | WO 2003-DK578   | 20030904 |
| W:                     | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW |                 |                 |          |
| RW:                    | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG   |                 |                 |          |
| CA 2499380             | AA   | 20040318        | CA 2003-2499380 | 20030904 |
| US 2004143006          | A1   | 20040722        | US 2003-654699  | 20030904 |
| EP 1537076             | A1   | 20050608        | EP 2003-793608  | 20030904 |
| R:                     | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK   |                 |                 |          |
| PRIORITY APPLN. INFO.: |  |                 |                 |          |
|                        |  | DK 2002-1301    | A               | 20020905 |
|                        |  | DK 2003-784     | A               | 20030523 |
|                        |  | US 2002-409814P | P               | 20020911 |
|                        |  | WO 2003-DK578   | W               | 20030904 |
| OTHER SOURCE(S):       | MARPAT 140:270625  |                 |                 |          |
| GI                     |  |                 |                 |          |

10/6931616 8/13/05

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 17:12:32 ON 13 AUG 2005

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 17:12:41 ON 13 AUG 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 AUG 2005 HIGHEST RN 860111-75-7

DICTIONARY FILE UPDATES: 12 AUG 2005 HIGHEST RN 860111-75-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*



Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10693161\10693161b.str



```

chain nodes :
1 2 3 4 5 7 8 9 11 12 15 16
chain bonds :
1-3 2-3 3-4 4-5 5-7 7-8 8-9 9-11 11-12 12-15 12-16
exact/norm bonds :
5-7 7-8 8-9 9-11 12-15 12-16
exact bonds :
1-3 2-3 3-4 4-5 11-12

```

G1:O,S

Match level :

```

1:Atom 2:Atom 3:CLASS 4:CLASS 5:CLASS 7:CLASS 8:Atom 9:CLASS 11:CLASS
12:CLASS 15:CLASS 16:CLASS

```

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*



Structure attributes must be viewed using STN Express query preparation.

=> s L1

SAMPLE SEARCH INITIATED 17:13:10 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 53506 TO ITERATE

3.7% PROCESSED 2000 ITERATIONS 2 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*INCOMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: EXCEEDS 1000000  
PROJECTED ANSWERS: EXCEEDS 632

L2 2 SEA SSS SAM L1

=> s L1 full

FULL SEARCH INITIATED 17:13:18 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - >1,000,000 TO ITERATE

< 93.6% PROCESSED 1000000 ITERATIONS 505 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.15

FULL FILE PROJECTIONS: ONLINE \*\*INCOMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: EXCEEDS 1000000  
PROJECTED ANSWERS: EXCEEDS 505

L3 505 SEA SSS FUL L1

=> fil caplus

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST  | 161.76           | 161.97        |

FILE 'CAPLUS' ENTERED AT 17:13:39 ON 13 AUG 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Aug 2005 VOL 143 ISS 8  
FILE LAST UPDATED: 12 Aug 2005 (20050812/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s L3

L4 3 L3

=> d ibib abs 1-3

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:370892 CAPLUS  
DOCUMENT NUMBER: 140:374984  
TITLE: Preparation of ((diaryllallyl)sulfanyl)phenoxy)acetic acids and esters as PPAR activators for treatment of diabetes and related conditions  
INVENTOR(S): Jeppesen, Lone; Mogensen, John Patrick; Petersson, Ingrid; Sauerberg, Per; Pihera, Pavel; Havranek, Miroslav  
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.  
SOURCE: PCT Int. Appl., 124 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

| PATENT NO.             | KIND   | DATE     | APPLICATION NO. | DATE       |
|------------------------|--|----------|-----------------|------------|
| WO 2004037776          | A2   | 20040506 | WO 2003-DK722   | 20031027   |
| WO 2004037776          | A3   | 20040610 |                 |            |
| W:                     | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW |          |                 |            |
| RW:                    | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG   |          |                 |            |
| US 2005070583          | A1   | 20050331 | US 2003-693161  | 20031024   |
| CA 2503280             | AA   | 20040506 | CA 2003-2503280 | 20031027   |
| EP 1558572             | A2   | 20050803 | EP 2003-757741  | 20031027   |
| R:                     | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK   |          |                 |            |
| PRIORITY APPLN. INFO.: |  |          | DK 2002-1631    | A 20021028 |
|                        |  |          | DK 2003-793     | A 20030526 |
|                        |  |          | US 2002-423467P | P 20021104 |
|                        |  |          | WO 2003-DK722   | W 20031027 |


OTHER SOURCE(S): MARPAT 140:374984  
GI

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:370891 CAPLUS  
DOCUMENT NUMBER: 140:391127  
TITLE: Preparation of biphenylallylsulfanylphenoxy)acetates and related compounds for treating peroxisome proliferator activated receptor (PPAR) mediated diseases  
INVENTOR(S): Jeppesen, Lone; Petersson, Ingrid; Sauerberg, Per; Pihera, Pavel; Havranek, Miroslav  
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.  
SOURCE: PCT Int. Appl., 69 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


| PATENT NO.             | KIND   | DATE     | APPLICATION NO. | DATE       |
|------------------------|--|----------|-----------------|------------|
| WO 2004037775          | A1   | 20040506 | WO 2003-DK723   | 20031027   |
| W:                     | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW |          |                 |            |
| RW:                    | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG   |          |                 |            |
| US 2005080115          | A1   | 20050414 | US 2003-692561  | 20031024   |
| CA 2503276             | AA   | 20040506 | CA 2003-2503276 | 20031027   |
| EP 1558571             | A1   | 20050803 | EP 2003-757742  | 20031027   |
| R:                     | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK   |          |                 |            |
| PRIORITY APPLN. INFO.: |  |          | DK 2002-1629    | A 20021028 |
|                        |  |          | US 2002-423644P | P 20021104 |
|                        |  |          | WO 2003-DK723   | W 20031027 |

OTHER SOURCE(S): MARPAT 140:391127  
GI



AB Title compds. [I; X1, X3 = (substituted) aryl, heteroaryl; X2, Ar = (substituted) aryl, arylene; Y1, Y2 = O, S; Z = (CH2)n; n = 1-3; R1 = H, halo, (substituted) alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, heteroalkyl, alkoxy, cycloalkoxy, alkylthio, etc.; R2 = H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, etc.], were prepared for treatment of PPAR mediated disease (no data). Thus, [4-[3,3-bis-(4-bromophenyl)allylsulfanyl]-2-methylphenoxy)acetic acid (preparation given),

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



AB Title compds. I [wherein X1 and X2 = independently (un)substituted (hetero)aryl; Ar = (un)substituted arylene; Y1 and Y2 = independently O or S; Z = (CH2)n; n = 1-3; R1 = H, halo, or optionally halo-substituted (cyclo)alkyl, alkenyl, alkynyl, (hetero)aralkyl, (cyclo)alkoxy, aryloxy, (hetero)aralkoxy, (cyclo)alkylthio, or arylthio; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, alkenyl, or aryl; or pharmaceutically acceptable salts, solvates, tautomeric forms, stereoisomers, mixts. of stereoisomers, or polymorphs thereof] were prepared as peroxisome proliferator activated receptors (PPAR) activators (no data). Thus, I and their pharmaceutical compns. are useful for the treatment and/or prevention of conditions mediated by PPAR, particularly subtype PPAR $\delta$ , such as diabetes, impaired glucose tolerance, insulin resistance, obesity, dyslipidemia, syndrome X, cardiovascular disease, and hypercholesterolemia (no data).  
For example, coupling of 4,4'-dibromobenzophenone with tri-*t*-butyl phosphonate in toluene and THF using NaH provided Et 3,3-bis(4-bromophenyl)acrylate (73%). Reduction of the ester to the alc. (76%) using DIBAL-H in THF and toluene, followed by reaction with (4-mercapto-2-methylphenoxy)acetic acid Me ester in the presence of ADPP and tributylphosphine in THF gave II (88%).

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Ph(OH)2, KF, Pd2(dba)3, and Pd(P(tBu)3)2 were stirred in THF to give [4-[3-biphenyl-4-yl-3-(4-bromophenyl)allylsulfanyl]phenoxy)acetic acid.

ACCESSION NUMBER: 2004:220310 CAPLUS  
DOCUMENT NUMBER: 140:270625TITLE: Preparation of  
[[[bis(biphenyl)allyl]oxy]phenoxy]acetic acids and analogs as PPAR $\delta$  agonists for  
treatment of diabetes and related conditions  
Jeppesen, Lone; Mogensen, John Patrick; Pettersson,  
Ingrid; Sauerberg, Per

PATENT ASSIGNEE(S): Novo Nordisk A/s, Den.

SOURCE: PCT Int. Appl., 78 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.    | KIND   | DATE     | APPLICATION NO. | DATE     |
|---------------|--|----------|-----------------|----------|
| WO 2004022533 | A1   | 20040318 | WO 2003-DK578   | 20030904 |
| W:            | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW |          |                 |          |
| RW:           | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CO, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG   |          |                 |          |
| CA 2499380    | AA   | 20040318 | CA 2003-2499380 | 20030904 |
| US 2004143006 | A1   | 20040722 | US 2003-654699  | 20030904 |
| EP 1537076    | A1   | 20050608 | EP 2003-793608  | 20030904 |
| R:            | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK   |          |                 |          |

PRIORITY APPLN. INFO.: DK 2002-1301 A 20020905



DK 2003-784 A 20030523

US 2002-409814P P 20020911

WO 2003-DK578 W 20030904

OTHER SOURCE(S): HARPAT 140:270625

GI



II

AB Title vinyl carboxylic acid deriva. I [wherein X<sup>1</sup> and X<sup>3</sup> = independently (un)substituted (hetero)aryl; X<sup>2</sup> and X<sup>4</sup> = independently (un)substituted (hetero)arylene; Ar = (un)substituted arylene; Y<sup>1</sup> and Y<sup>2</sup> = independently

O or S; Z = (CH<sub>2</sub>)<sub>n</sub>; n = 1-3; R<sup>1</sup> = H, halo, or (un)substituted (cyclo)alkyl, alkynyl, alkynyl, (hetero)alkyl, (cyclo)alkoxy, aryloxy, (hetero)alkoxy, (cyclo)alkylthio, arylthio; R<sup>2</sup> = H, (cyclo)alkyl, alkynyl, alkynyl, or aryl; or pharmaceutically acceptable salts, solvates,

tautomers, stereoisomers, or polymorphs thereof] were prepared as peroxisome

proliferator-activated receptor  $\delta$  (PPAR $\delta$ ) agonists (no data).

For example, 4,4'-dibromobenzophenone was coupled with tri-*i*-Et phosphonoacetate in the presence of NaH in toluene to give Et 3,3-bis(4-bromophenyl)acrylate (73%). Reduction using DIBAL-H in THF (76%),

followed by ADEP-catalyzed condensation with (4-mercapto-2-methylphenoxy)acetic acid Me ester in THF (88%) afforded [4-[3,3-bis(4-bromophenyl)allyl]sulfanyl]-2-methylphenoxy)acetic acid Me ester. Saponification (93%) and substitution with phenylboronic acid using KF,


Pd(dba)<sub>3</sub>, and Pd(P(t-Bu)<sub>3</sub>)<sub>2</sub> in THF (53%) provided II. Also disclosed is the use of I and their pharmaceutical compns. for the treatment of PPAR $\delta$ -mediated conditions, such as diabetes, impaired glucose tolerance, insulin resistance, or obesity (no data).

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

=>

Uploading C:\Program Files\Stnexp\Queries\10693161\10693161c.str



chain nodes :

1 2 3 5 6 7 9 10 13 14

ring nodes :

15 16 17 18 19 20 21 22 23 24 25 26

chain bonds :

1-2 1-15 1-21 2-3 3-5 5-6 6-7 7-9 9-10 10-13 10-14

ring bonds :

15-16 15-20 16-17 17-18 18-19 19-20 21-22 21-26 22-23 23-24 24-25 25-26

exact/norm bonds :

3-5 5-6 6-7 7-9 10-13 10-14

exact bonds :

1-2 1-15 1-21 2-3 9-10

normalized bonds :

15-16 15-20 16-17 17-18 18-19 19-20 21-22 21-26 22-23 23-24 24-25 25-26

G1:O,S

Match level :

1:CLASS 2:CLASS 3:CLASS 5:CLASS 6:Atom 7:CLASS 9:CLASS 10:CLASS 13:CLASS  
14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom  
23:Atom 24:Atom 25:Atom 26:Atom

L5 STRUCTURE UPLOADED

=> fil reg

COST IN U.S. DOLLARS

| SINCE FILE | TOTAL   |
|------------|---------|
| ENTRY      | SESSION |
| 9.75       | 171.72  |

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

| SINCE FILE | TOTAL   |
|------------|---------|
| ENTRY      | SESSION |
| -2.19      | -2.19   |

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 17:15:54 ON 13 AUG 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 12 AUG 2005 HIGHEST RN 860111-75-7

DICTIONARY FILE UPDATES: 12 AUG 2005 HIGHEST RN 860111-75-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*


Structure search iteration limits have been increased. See HELP SLIMITS  
for details.

Experimental and calculated property data are now available. For more  
information enter HELP PROP at an arrow prompt in the file or refer  
to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10693161\10693161c.str



chain nodes :

1 2 3 5 6 7 9 10 13 14

ring nodes :

15 16 17 18 19 20 21 22 23 24 25 26

chain bonds :

1-2 1-15 1-21 2-3 3-5 5-6 6-7 7-9 9-10 10-13 10-14

ring bonds :

15-16 15-20 16-17 17-18 18-19 19-20 21-22 21-26 22-23 23-24 24-25 25-26

exact/norm bonds :

3-5 5-6 6-7 7-9 10-13 10-14

exact bonds :  
1-2 1-15 1-21 2-3 9-10  
normalized bonds :  
15-16 15-20 16-17 17-18 18-19 19-20 21-22 21-26 22-23 23-24 24-25 25-26

G1:O,S

Match level :  
1:CLASS 2:CLASS 3:CLASS 5:CLASS 6:Atom 7:CLASS 9:CLASS 10:CLASS 13:CLASS  
14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom  
23:Atom 24:Atom 25:Atom 26:Atom

L6 STRUCTURE UPLOADED

=> d  
L6 HAS NO ANSWERS  
L6 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s L6  
SAMPLE SEARCH INITIATED 17:16:24 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 158 TO ITERATE

100.0% PROCESSED 158 ITERATIONS 25 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 2406 TO 3914  
PROJECTED ANSWERS: 200 TO 800

L7 25 SEA SSS SAM L6

=> s L6 full  
FULL SEARCH INITIATED 17:16:31 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 3372 TO ITERATE

100.0% PROCESSED 3372 ITERATIONS 505 ANSWERS  
SEARCH TIME: 00.00.01

L8 505 SEA SSS FUL L6

|  |            |         |
|--|------------|---------|
| => fil caplus                              |            |         |
| COST IN U.S. DOLLARS                       | SINCE FILE | TOTAL   |
|  | ENTRY      | SESSION |
| FULL ESTIMATED COST                        | 161.33     | 333.05  |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE | TOTAL   |
|  | ENTRY      | SESSION |
| CA SUBSCRIBER PRICE                        | 0.00       | -2.19   |

FILE 'CAPLUS' ENTERED AT 17:16:37 ON 13 AUG 2005



USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Aug 2005 VOL 143 ISS 8  
FILE LAST UPDATED: 12 Aug 2005 (20050812/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s L8  
L9            3 L8  
  
=> d ibib abs 1-3

L9 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS ON STN

ACCESSION NUMBER: 2004:370892 CAPLUS

DOCUMENT NUMBER: 140:374984

TITLE: Preparation of [[diaryllallyl]sulfanyl]phenoxy]acetic acids and esters as PPAR activators for treatment of diabetes and related conditions  
Jeppesen, Lone; Mogensen, John Patrick; Petersson, Ingrid; Sauerberg, Per; Pihers, Pavel; Havranek, Miroslav

INVENTOR(S):

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.

SOURCE: PCT Int. Appl., 124 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.    | KIND | DATE     | APPLICATION NO. | DATE     |
|---------------|------|----------|-----------------|----------|
| WO 2004037776 | A2   | 20040506 | WO 2003-DK722   | 20031027 |
| WO 2004037776 | A3   | 20040610 |                 |          |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005070583 A1 20050331 US 2003-693161 20031024

CA 2503280 AA 20040506 CA 2003-2503280 20031027

EP 1558572 A2 20050803 EP 2003-757741 20031027

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.: DK 2002-1631 A 20021028

DK 2003-793 A 20030526



US 2002-423467P P 20021104

WO 2003-DK722 W 20031027

OTHER SOURCE(S): MARPAT 140:374984

GI

L9 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)




AB Title compds. I [wherein X1 and X2 = independently (un)substituted (hetero)aryl; Ar = (un)substituted arylene; Y1 and Y2 = independently O or

S; Z = (CH2)n; n = 1-3; R1 = H, halo, or optionally halo-substituted (cyclo)alkyl, alkenyl, alkynyl, (hetero)aryl, (cyclo)alkoxy, aryloxy, (hetero)alkoxy, (cyclo)alkylthio, or arylthio; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, alkenyl, or aryl; or pharmaceutically acceptable salts, solvates, tautomeric forms, stereoisomers, mixts. of stereoisomers,

or polymorphs thereof] were prepared as peroxisome proliferator activated receptors (PPAR) activators (no data). Thus, I and their pharmaceutical compns. are useful for the treatment and/or prevention of conditions mediated by PPAR, particularly subtype PPAR $\delta$ , such as diabetes, impaired glucose tolerance, insulin resistance, obesity, dyslipidemia, syndrome X, cardiovascular disease, and hypercholesterolemia (no data).

For example, coupling of 4,4'-dibromobenzophenone with tri-Et phosphonacetate in toluene and THF using NaH provided Et 3,3-bis(4-bromophenyl)acrylate (73%). Reduction of the ester to the alc. (76%) using DIBAL-H in THF and toluene, followed by reaction with (4-mercapto-2-methylphenoxy)acetic acid Me ester in the presence of ADPP and tributylphosphine in THF gave II (88%).



AB Title compds. [I; X1, X3 = (substituted) aryl, heteroaryl; X2, Ar = (substituted) aryl, arylene; Y1, Y2 = O, S; Z = (CH2)n; n = 1-3; R1 = H, halo, (substituted) alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, heteroalkyl, alkoxy, cycloalkoxy, alkylthio, etc.; R2 = H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, etc.] were prepared for treatment of PPAR mediated disease (no data). Thus, [4-[3,3-bis-(4-bromophenyl)allylsulfanyl]-2-methylphenoxy]acetic acid (preparation given),

ACCESSION NUMBER: 2004:220310 CAPLUS

DOCUMENT NUMBER: 140:270625

TITLE: Preparation of

[[[bis(biphenyl)allyl]oxy]phenoxy]acetic acids and analogs as PPAR $\delta$  agonists for treatment of diabetes and related conditions

Jeppesen, Lone; Mogensen, John Patrick; Pettersson, Ingrid; Sauerberg, Per

PATENT ASSIGNER(S): Novo Nordisk A/s, Den.

SOURCE: PCT Int. Appl., 78 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.             | KIND   | DATE     | APPLICATION NO. | DATE       |
|------------------------|--|----------|-----------------|------------|
| WO 2004022533          | A1   | 20040318 | WO 2003-DK578   | 20030904   |
| W:                     | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW |          |                 |            |
| RW:                    | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CN, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG   |          |                 |            |
| CA 2499380             | AA   | 20040318 | CA 2003-2499380 | 20030904   |
| US 2004143006          | A1   | 20040722 | US 2003-654699  | 20030904   |
| EP 1537076             | A1   | 20050608 | EP 2003-793608  | 20030904   |
| R:                     | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LT, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK   |          |                 |            |
| PRIORITY APPLN. INFO.: |  |          | DK 2002-1301    | A 20020905 |
|                        |  |          | DK 2003-784     | A 20030523 |
|                        |  |          | US 2002-409814P | P 20020911 |
|                        |  |          | WO 2003-DK578   | W 20030904 |

OTHER SOURCE(S): MARPAT 140:270625

GI



II

AB Title vinyl carboxylic acid derivs. I (wherein X1 and X3 = independently (un)substituted (hetero)aryl; X2 and X4 = independently (un)substituted (hetero)arylene; Ar = (un)substituted arylene; Y1 and Y2 = independently

O or S; Z = (CH<sub>2</sub>)<sub>n</sub>; n = 1-3; R1 = H, halo, or (un)substituted (cyclo)alkyl, alkanyl, alkynyl, (hetero)alkoxy, (cyclo)alkoxy, aryloxy, (hetero)aralkoxy, (cyclo)alkylthio, arylthio; R2 = H, (cyclo)alkyl, alkanyl, alkynyl, or aryl; or pharmaceutically acceptable salts, solvates, tautomers, stereoisomers, or polymorphs thereof] were prepared as

peroxisome proliferator-activated receptor  $\delta$  (PPAR $\delta$ ) agonists (no data). For example, 4,4'-dibromobenzophenone was coupled with tri-*i*-Et phosphonacetate in the presence of NaH in toluene to give Et 3,3-bis(4-bromophenyl)acrylate (73%). Reduction using DIBAL-H in THF

(76%), followed by ADDP-catalyzed condensation with (4-mercapto-2-methylphenoxy)acetic acid Me ester in THF (88%) afforded [4-[3,3-bis(4-bromophenyl)allylsulfanyl]-2-methylphenoxy]acetic acid Me ester. Saponification (93%) and substitution with phenylboronic acid using K<sub>2</sub> Pd(dba)<sub>3</sub> and Pd(P(*t*-Bu))<sub>2</sub> in THF (53%) provided II. Also disclosed is the use of I and their pharmaceutical compns. for the treatment of PPAR $\delta$ -mediated conditions, such as diabetes, impaired glucose tolerance, insulin resistance, or obesity (no data).

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

=> fil reg

COST IN U.S. DOLLARS

| SINCE FILE | TOTAL   |
|------------|---------|
| ENTRY      | SESSION |
| 9.75       | 342.80  |

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

| SINCE FILE | TOTAL   |
|------------|---------|
| ENTRY      | SESSION |
| -2.19      | -4.38   |

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 17:19:11 ON 13 AUG 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 AUG 2005 HIGHEST RN 860111-75-7

DICTIONARY FILE UPDATES: 12 AUG 2005 HIGHEST RN 860111-75-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.



\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10693161\10693161d.str



chain nodes :  
 1 2 3 5 6 7 9 10 13 14 15 16  
 chain bonds :  
 1-2 1-15 1-16 2-3 3-5 5-6 6-7 7-9 9-10 10-13 10-14  
 exact/norm bonds :  
 1-15 1-16 3-5 5-6 6-7 7-9 10-13 10-14  
 exact bonds :  
 1-2 2-3 9-10

G1:O,S

Match level :  
 1:CLASS 2:CLASS 3:CLASS 5:CLASS 6:Atom 7:CLASS 9:CLASS 10:CLASS 13:CLASS  
 14:CLASS 15:Atom 16:Atom

L10 STRUCTURE UPLOADED

=> d  
L10 HAS NO ANSWERS  
L10 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s L10  
SAMPLE SEARCH INITIATED 17:19:28 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 53506 TO ITERATE

3.7% PROCESSED 2000 ITERATIONS 0 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*INCOMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: EXCEEDS 1000000  
PROJECTED ANSWERS: EXCEEDS 0

L11 0 SEA SSS SAM L10

=> s L10 full  
FULL SEARCH INITIATED 17:19:33 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - >1,000,000 TO ITERATE

< 93.6% PROCESSED 1000000 ITERATIONS 8 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.14

FULL FILE PROJECTIONS: ONLINE \*\*INCOMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: EXCEEDS 1000000  
PROJECTED ANSWERS: EXCEEDS 8

L12 8 SEA SSS FUL L10

|  |            |         |
|--|------------|---------|
| => fil caplus                              |            |         |
| COST IN U.S. DOLLARS                       | SINCE FILE | TOTAL   |
|  | ENTRY      | SESSION |
| FULL ESTIMATED COST                        | 161.33     | 504.13  |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE | TOTAL   |
|  | ENTRY      | SESSION |
| CA SUBSCRIBER PRICE                        | 0.00       | -4.38   |

FILE 'CAPLUS' ENTERED AT 17:19:53 ON 13 AUG 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the

American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Aug 2005 VOL 143 ISS 8  
FILE LAST UPDATED: 12 Aug 2005 (20050812/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s L12

L13            2 L12

=> d ibib abs 1-2


L13 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS ON STN

ACCESSION NUMBER: 2004:370892 CAPLUS  
DOCUMENT NUMBER: 140:374984  
TITLE: Preparation of ((diaryllallyl)sulfanyl)phenoxy)acetic acids and esters as PPAR activators for treatment of diabetes and related conditions  
INVENTOR(S): Jeppesen, Lone; Mogensen, John Patrick; Pettersson, Ingrid; Sauerberg, Per; Pihers, Pavel; Havranek, Miroslav  
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.  
SOURCE: PCT Int. Appl., 124 pp.  
CODEN: PIXX02  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE     |
|---|------|----------|-----------------|----------|
| WO 2004037776   | A2   | 20040506 | WO 2003-DK722   | 20031027 |
| WO 2004037776   | A3   | 20040610 |                 |          |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW |      |          |                 |          |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  |      |          |                 |          |
| US 2005070583   | A1   | 20050331 | US 2003-693161  | 20031024 |
| CA 2503280  | AA   | 20040506 | CA 2003-2503280 | 20031027 |
| EP 1558572  | A2   | 20050803 | EP 2003-757741  | 20031027 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK   |      |          |                 |          |
| PRIORITY APPLN. INFO.: DK 2002-1631 A 20021028  |      |          |                 |          |
| DK 2003-793 A 20030526  |      |          |                 |          |
| US 2002-423467P P 20021104  |      |          |                 |          |
| WO 2003-DK722 W 20031027  |      |          |                 |          |

OTHER SOURCE(S): MARPAT 140:374984  
GI

L13 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)




AB Title compds. I (wherein X1 and X2 = independently (un)substituted (hetero)aryl; Ar = (un)substituted arylene; Y1 and Y2 = independently O or S; Z = (CH2)n; n = 1-3; R1 = H, halo, or optionally halo-substituted (cyclo)alkyl, alkenyl, alkynyl, (hetero)alkyl, (cyclo)alkoxy, aryloxy, (hetero)alkoxy, (cyclo)alkylthio, or arylthio; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, alkenyl, or aryl; or pharmaceutically acceptable salts, solvates, tautomeric forms, stereoisomers, mixts. of stereoisomers, or polymorphs thereof) were prepared as peroxisome proliferator activated receptors (PPAR) activators (no data). Thus, I and their pharmaceutical compns. are useful for the treatment and/or prevention of conditions mediated by PPAR, particularly subtype PPAR $\delta$ , such as diabetes, impaired glucose tolerance, insulin resistance, obesity, dyslipidemia, syndrome X, cardiovascular disease, and hypercholesterolemia (no data).  
For example, coupling of 4,4'-dibromobenzophenone with tri-Et phosphonacetate in toluene and THF using NaH provided Et 3,3-bis(4-bromophenyl)acrylate (73%). Reduction of the ester to the alc. (76%) using DIBAL-H in THF and toluene, followed by reaction with (4-mercapto-2-methylphenoxy)acetic acid Me ester in the presence of ADEP and tributylphosphine in THF gave II (88%).

L13 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS ON STN

ACCESSION NUMBER: 2004:370891 CAPLUS  
DOCUMENT NUMBER: 140:391127  
TITLE: Preparation of biphenylallylsulfanylphenoxy)acetates and related compounds for treating peroxisome proliferator activated receptor (PPAR) mediated diseases  
INVENTOR(S): Jeppesen, Lone; Pettersson, Ingrid; Sauerberg, Per; Pihers, Pavel; Havranek, Miroslav  
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.  
SOURCE: PCT Int. Appl., 69 pp.  
CODEN: PIXX02  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE     |
|---|------|----------|-----------------|----------|
| WO 2004037775   | A1   | 20040506 | WO 2003-DK723   | 20031027 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW |      |          |                 |          |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  |      |          |                 |          |
| US 2005080115   | A1   | 20050414 | US 2003-692561  | 20031024 |
| CA 2503276  | AA   | 20040506 | CA 2003-2503276 | 20031027 |
| EP 1558571  | A1   | 20050803 | EP 2003-757742  | 20031027 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK   |      |          |                 |          |
| PRIORITY APPLN. INFO.: DK 2002-1629 A 20021028  |      |          |                 |          |
| US 2002-423644P P 20021104  |      |          |                 |          |
| WO 2003-DK723 W 20031027  |      |          |                 |          |

OTHER SOURCE(S): MARPAT 140:391127  
GI



AB Title compds. [I; X1, X3 = (substituted) aryl, heteroaryl; X2, Ar = (substituted) aryl, arylene; Y1, Y2 = O, S; Z = (CH2)n; n = 1-3; R1 = H, halo, (substituted) alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, heteroalkyl, alkoxy, cycloalkoxy, alkylthio, etc.; R2 = H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, etc.], were prepared for treatment of PPAR mediated disease (no data). Thus, (4-[3,3-bis(4-bromophenyl)allylsulfanyl]-2-methylphenoxy)acetic acid (preparation given).

L13 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)

PhB(OH)2, KF, Pd2(dba)3, and Pd[P(tBu)3]2 were stirred in THF to give [4-[3-biphenyl-4-yl-3-(4-bromophenyl)allylsulfanyl]phenoxy)acetic acid.



=> d ibib abs 1-2 fhitstr

ACCESSION NUMBER: 2004:370892 CAPLUS

DOCUMENT NUMBER: 140:374984

TITLE: Preparation of ((diaryllallyl)sulfanyl)phenoxy]acetic acids and esters as PPAR activators for treatment of diabetes and related conditions

INVENTOR(S): Jeppesen, Lone; Mogensen, John Patrick; Pettersson, Ingrid; Sauerberg, Per; Pihera, Pavel; Havranek, Miroslav

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.  
SOURCE: PCT Int. Appl., 124 pp.  
CODEN: PIXX02

DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

| PATENT NO.             | KIND   | DATE     | APPLICATION NO. | DATE       |
|------------------------|--|----------|-----------------|------------|
| WO 2004037776          | A2   | 20040506 | WO 2003-DK722   | 20031027   |
| WO 2004037776          | A3   | 20040610 |                 |            |
| W:                     | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW |          |                 |            |
| RW:                    | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG   |          |                 |            |
| US 2005070583          | A1   | 20050331 | US 2003-693161  | 20031024   |
| CA 2503280             | AA   | 20040506 | CA 2003-2503280 | 20031027   |
| EP 1558572             | A2   | 20050803 | EP 2003-757741  | 20031027   |
| R:                     | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK   |          |                 |            |
| PRIORITY APPLN. INFO.: |  |          | DK 2002-1631    | A 20021028 |
|                        |  |          | DK 2003-793     | A 20030526 |
|                        |  |          | US 2002-423467P | P 20021104 |
|                        |  |          | WO 2003-DK722   | W 20031027 |

OTHER SOURCE(S): MARPAT 140:374984

GI

(Continued)



AB Title compds. I [wherein X1 and X2 = independently (un)substituted (hetero)aryl; Ar = (un)substituted arylene; Y1 and Y2 = independently O or

S; Z = (CH2)n; n = 1-3; R1 = H, halo, or optionally halo-substituted (cyclo)alkyl, alkenyl, alkynyl, (hetero)alkyl, (cyclo)alkoxy, aryloxy, (hetero)aralkoxy, (cyclo)alkylthio, or arylthio; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, alkenynyl, or aryl; or pharmaceutically acceptable salts, solvates, tautomeric forms, stereoisomers, mixts. of stereoisomers,

or polymorphs thereof] were prepared as peroxisome proliferator activated receptors (PPAR) activators (no data). Thus, I and their pharmaceutical compns. are useful for the treatment and/or prevention of conditions mediated by PPAR, particularly subtype PPAR $\delta$ , such as diabetes, impaired glucose tolerance, insulin resistance, obesity, dyslipidemia, syndrome X, cardiovascular disease, and hypercholesterolemia (no data).

For example, coupling of 4,4'-dibromobenzophenone with tri-Et phosphonacetate in toluene and THF using NaH provided Et 3,3-bis(4-bromophenyl)acrylate (73a). Reduction of the ester to the alc. (76%) using DIBAL-H in THF and toluene, followed by reaction with (4-mercapto-2-methylphenoxy)acetic acid in the presence of ADMP and tributylphosphine in THF gave II (88%).

IT 685119-48-4P, [4-[[[3-bis(3-methylthiophen-2-yl)allyl]sulfanyl]-2-trifluoromethylphenoxy]acetic acid  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PPAR activator; preparation of ((diaryllallyl)sulfanyl)phenoxy]acetates as PPAR activators for treatment of diabetes and related conditions)

RN 685119-48-4 CAPLUS  
CN Acetic acid, [4-[[[3-bis(3-methyl-2-thienyl)-2-propenyl]thio]-2-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)

ACCESSION NUMBER: 2004:370891 CAPLUS

DOCUMENT NUMBER: 140:391127

TITLE: Preparation of biphenylallylsulfanylphenoxyacetates and related compounds for treating peroxisome proliferator activated receptor (PPAR) mediated diseases

INVENTOR(S): Jeppesen, Lone; Pettersson, Ingrid; Sauerberg, Per; Pihera, Pavel; Havranek, Miroslav

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.  
SOURCE: PCT Int. Appl., 69 pp.  
CODEN: PIXX02


DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.             | KIND   | DATE     | APPLICATION NO. | DATE       |
|------------------------|--|----------|-----------------|------------|
| WO 2004037775          | A1   | 20040506 | WO 2003-DK723   | 20031027   |
| W:                     | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW |          |                 |            |
| RW:                    | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG   |          |                 |            |
| US 2005080115          | A1   | 20050414 | US 2003-692561  | 20031024   |
| CA 2503276             | AA   | 20040506 | CA 2003-2503276 | 20031027   |
| EP 1558571             | A1   | 20050803 | EP 2003-757742  | 20031027   |
| R:                     | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK   |          |                 |            |
| PRIORITY APPLN. INFO.: |  |          | DK 2002-1629    | A 20021028 |
|                        |  |          | US 2002-423644P | P 20021104 |
|                        |  |          | WO 2003-DK723   | W 20031027 |


OTHER SOURCE(S): MARPAT 140:391127

GI



AB Title compds. [I; X1, X3 = (substituted) aryl, heteroaryl; X2, Ar = (substituted) aryl, arylene; Y1, Y2 = O, S; Z = (CH2)n; n = 1-3; R1 = H, halo, (substituted) alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, heteroalkyl, alkoxy, cycloalkoxy, alkylthio, etc.; R2 = H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, etc.], were prepared for treatment of PPAR mediated disease (no data). Thus, [4-[[[3-bis(4-bromophenyl)allylsulfanyl]-2-methylphenoxy]acetic acid (preparation given),

L13 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 PhB(OH)2, KP, Pd2(dbe)3, and Pd[P(tBu)3]2 were stirred in THF to give  
 [4-{3-biphenyl-4-yl-3-(4-bromophenyl)allylsulfanyl}phenoxy]acetic acid.  
 IT 686774-28-7p  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (preparation of biphenylallylsulfanylphenoxyacetates and related  
 compds. for  
 treating peroxisome proliferator activated receptor (PPAR) mediated  
 diseases)  
 RN 686774-28-7 CAPLUS  
 CN Acetic acid,  
 [2-methyl-4-([3-{5-(5-methyl-2-thienyl)-2-benzofuranyl}-3-(2-  
 thienyl)-2-propenyl]thio)phenoxy]- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS

SINCE FILE  
ENTRY  
16.08

TOTAL  
SESSION  
520.21

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE  
ENTRY  
-2.92

TOTAL  
SESSION  
-7.30

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 17:20:53 ON 13 AUG 2005